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resumo 
 
 
Face a todos os desafios relacionados com a produção e logística do 
medicamento experimental, este projeto tem como objetivo fornecer uma visão 
geral sobre o desenvolvimento de um medicamento experimental, assim como 
os principais detalhes que devem ser considerados na preparação, embalagem, 
rotulagem e distribuição de medicamentos experimentais, de forma a fornecer 
uma ferramenta de referência rápida em contexto profissional e académico. 
Foi realizada uma revisão na literatura internacional para identificar estudos com 
foco no desenvolvimento e distribuição de medicamentos experimentais, 
principalmente através de bases de dados como o PubMed e Medline, embora 
também se tenha recorrido a guidelines, e alguns livros e teses de mestrado e 
doutoramento sobre o objeto de estudo. Foram selecionados apenas artigos na 
língua inglesa. Sempre que possível, foram selecionados os artigos mais 
recentes.  
Durante o processo de desenvolvimento de um medicamento experimental, os 
estudos de solubilidade, assim como os de biodisponibilidade e bioequivalência, 
são os maiores desafios nas fases iniciais de desenvolvimento. Atendendo à 
produção do medicamento experimental, aspectos críticos, como os 
comparadores, os processos de blinding e embalamento, são determinantes 
para o sucesso de todo o ensaio clínico. Após a completa preparação do 
medicamento experimental, este é introduzido nas diferentes fases de ensaio 
clínico, com o objetivo de fornecer uma ampla informação, como a eficácia e a 
segurança. Todo este processo deve englobar uma série de requisitos 
previamente estabelecidos, assim como uma equipa devidamente treinada, de 
forma a minimizar os custos associados ao desenvolvimento do medicamento 
experimental, acelerando a sua entrada no mercado.  
É importante ressalvar que embora exista uma ampla gama de informação 
sobre a preparação de medicamentos experimentais, foi encontrada pouca 
informação sobre a logística, sendo fundamental, no futuro, explorar mais a 
temática da distribuição de medicamentos experimentais, abordando os 
principais resultados não satisfatórios das auditorias, no âmbito dos ensaios 
clínicos, e encontrar ferramentas e procedimentos para evitar as não-
conformidades. 
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abstract 
 
 
Duo to all of the challenges related with the production and logistics of the 
investigational medicinal products, this project aims to make an overview about 
the development of an investigational medicinal product, and the main details 
that must be considered in the preparation, packaging, labelling and distribution 
of investigational medicinal products, in order to provide a quick reference tool in 
a professional and academic context.  
A review was made in the international literature to identify studies focusing on 
development and handling of investigational medicinal products, mainly through 
PubMed and Medline databases, although it has also resorted to guidelines, 
some books on the subject, and master and doctoral thesis. Only English 
language papers were selected. Whenever possible, it were selected the most 
recent articles.  
During the development of IMP, solubility, as well as bioavailability assessment 
and bioequivalence studies, are the most challenging steps in the early phase of 
preparation of IMPs. Concerning the IMP production, the critical aspects, such as 
comparators, blinding and package, will determine the success of the entire 
clinical trial. When the IMP is fully prepared, it enters in the different clinical trials 
phases, with the aim of providing a range of information, such as efficacy and 
safety. This whole process must meet a series of requirements previously 
established, and adequate trained staff, in order to minimize the costs associated 
with the development of the IMP, as well as accelerate its market entry. 
It is important to note some limitations in the review. Although there is a wide 
range of information on the preparation of investigational medicinal products, 
little information was found on the logistics. In a future work, it would be 
interesting to further explore the distribution of investigational medicinal products, 
addressing the main unsatisfactory results of audits, in a clinical trial 
environment, and find tools and procedures to prevent nonconformities.  
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CHAPTER	  1	  
Introduction	  
 
Human curiosity has been the driver force for the advancement of science and medicine 
since these disciplines came into existence. In addition, human subjects have been used to 
substantiate the innovate theories involved in the pursuit of this knowledge.  
The birth of the modern-day clinical trials is usually considered to be the publication by the 
United Kingdom Medical Research Council in 1948 of a trial for the treatment of 
pulmonary tuberculosis with streptomycin [1]. In any case, the comparative concept of 
assessing therapeutic efficacy has been known from the Old Testament [1, 2], but it was 
during the fourteenth to sixteenth centuries, in the Renaissance period, that the great 
development in many forms ranging from art to science took place [1]. 
The most famous historical example of a planned, prospective controlled, comparative, 
clinical trial is from the eighteenth-century: where Lind found oranges and lemons to be the 
most effective of six dietary treatments for scurvy on board ships [1, 2]. In the nineteenth-
century, a clinician and pathologist, Pierre Charles Alexandre Louis, introduced the 
numerical aspect to comparing treatments [1], but, it was more than a century later when 
Bradford Hill used a formal randomization procedure for creating groups of cases that were 
“in all respects alike, except in the treatment” [1]. The randomization was a major 
contribution for the design of experimental studies and it refers to a scenario where patients 
are divided into groups and then the treatment for each group is randomly assigned [1]. 
However, beyond the randomization procedure, it also matters to highlight blinding, 
because today such procedures are considered the most important aspect of good, well-
controlled clinical trials, unless the studies are to be open label, thus, not blinded. Blinding 
consist in a process of keeping hidden certain information about data, drugs or study 
procedures in order to help avoid bias. Most commonly this means keeping the treatment 
allocation hidden from the investigators and subjects (and often data management staff) 
taking part in, and managing a study [3].  
Although clinical trials have an ancient history, it was in June 1964 that the World Medical 
Association has developed the Declaration of Helsinki as a statement of ethical principles 
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to provide guidance to physicians and other participants in medical research involving 
human subjects. One of the principal topics of this declaration mentions that it is the duty of 
the physician to promote and safeguard the health of the subject. The physician’s 
knowledge and conscience are dedicated to the fulfilment of this duty. Further, subjects will 
know exactly what to expected from a clinical study and from their participation, such as 
risks and benefits and that is why all have to provide informed consent before the clinical 
trial starts.  
Nowadays, all clinical trials must be in compliance with the Declaration of Helsinki and 
there is a battery of regulatory legislation and guidelines that establishes all requirements 
and steps for the different clinical trials phases [4].  
Since World War II, the clinical trial has evolved into a standard procedure in the 
evaluation of new drugs. Its features include the use of a control group of patients that do 
not receive the experimental treatment (the so called placebo group, when the study is to be 
placebo-controlled), the random allocation of patients to the different treatments, including 
the control group, and the use of blinded assessment. The clinical trial illustrates the desire 
of modern society to justify its medical choices on the basis of the objectivity inherent in 
statistical and quantitative data assessments, in support of an outcome for drug efficacy, 
and safety. 
The major challenge of any drug discovery program is to bring together a cross section of 
talented, multidisciplinary scientists involved in evaluating and characterizing the 
pharmacological profile of a new drug entity [5]. The basic principles involve defining the 
mechanism of action, potency, efficacy, safety, toxicology, and metabolism of lead 
compound [5], in the first instance. The determination of the structural characteristics that 
may provide the desired biological activity, may be based on a rational drug design 
approach and classical structure-biological activity relationship [5]. However, nowadays, 
highly advanced computer technology allows a molecular approach based on computational 
of chemical entities, which may “fit” the active moiety of, for example, the selected and 
validated target enzyme, membrane receptor site, or a clearly characterized gene sequence 
[5]. In a following step, the compounds are evaluated by biochemists, cell biologists, 
pharmacologists, or biotechnologists using various in vitro screening assays (enzymes, 
membrane receptors, cellular organelles or isolated tissue preparations) to determine the 
intrinsic activity of the drug candidate [5]. In other words, the leads compounds are 
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optimized to generate the candidate. A drug candidate suitable for clinical testing is 
expected to bind selectively to the receptor site on the target, to elicit the desired functional 
response of the target molecule, and to have adequate bioavailability and biodistribution to 
elicit the desired responses in animals and humans; it must also pass formal toxicity 
evaluation in animals [6]. The path from lead to clinical drug candidate represents the most 
idiosyncratic segment of drug discovery and development [6]. Once the in vitro assessment 
has identified “active leads”, the process goes on to in vivo testing of the drug candidate in 
appropriate animal models that best predicts the compound’s ability to alter a particular 
disease target in humans [5].  In other words, the main goals of this process are to 
demonstrate the biological activity of the drug, to establish the therapeutic index by 
carrying out safety assessments in various species. Furthermore, analytical chemistry drives 
are the identification and characterization of potential metabolites that are produced by the 
parent compound [5], as well as potential by products and other sort of potential impurities. 
The various stages of preclinical studies involve a multidisciplinary expertise and the 
clinical pharmacologist group interacts with the preclinical scientists to remain informed of 
the findings of the drug candidate. All information is valuable to determine the first dose in 
Phase I clinical trials [5] and support pharmaceutical development to generate and provide 
information about formulation, manufacturing process, analytic and stability.    
Preclinical studies of potential new medicines were relatively superficial until several 
disasters had occurred, in particular the thalidomide catastrophe in the 1960s, where 
exposure to this compound during early pregnancy resulted in limb deformities in 
developing embryos [7]. Further, early clinical studies were generally considered very safe 
until in March 2006, when several volunteers experienced severe immunological reactions 
after a first treated with TGN1412, a CD28 antibody, which, in hindsight, had been 
administered at a too high dose [7]. Today there are national and international regulations 
that require sponsors to provide information from a detailed package of preclinical studies, 
before they can apply for and start a clinical development program. Furthermore, although 
most investigators have heard of Good Clinical Practices (GCP), the interpretation of its 
meaning can vary enormously. In fact, the primary reason for the presence of a GCP code 
is the protection of human rights [4, 8]. Pressure to increase profits, cut drug development 
costs, and shorten regulatory approval times should not force the pharmaceutical industry to 
adopt a shameless “profit-over-people” [9].  
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After the preparation of the drug substance, pre-formulation and analytical studies for both 
the active and control substance, as well as the initial formulation, together with 
preliminary degradation studies and stability assessment are needed before the clinical 
program starts. All activities are lined up to support manufacture, control and release of the 
investigational medicinal product (IMP) for the clinical trials. According to the Portuguese 
Decree-Law number 176/2006 of 30 August and the European Directive [10] an IMP is 
defined as a “pharmaceutical form of an active substance or placebo, tested or used as a 
reference in a clinical trial, including drugs whose marketing there been authorized but are 
used or prepared on the dosage form or packaging, so different from the authorized form, or 
used for an unauthorized indication or for more information about the authorized form”.  
In clinical trials there may be added risk to participating subjects compared to patients 
treated with marketed products. So, it is crucial that IMP should be produced in accordance 
with the principles and the detailed guidelines of Good Manufacturing Practices (GMP) for 
Medicinal Products [11]. The application of GMP to the manufacturing of IMPs is intended 
“to ensure that trial subjects are not placed at risk, and that the results of clinical trials are 
unaffected by inadequate safety, quality or efficacy arising from unsatisfactory 
manufacture”. Furthermore, the application of GMP should ensure “that there is 
consistency between batches of the same IMP used in the same or different clinical trials, 
and that changes during the development of an IMP are adequately documented and 
justified” [11].  
The production of IMP involve complexity and various challenges in comparison to 
marketed products, due of the lack of fixed routines, variety of clinical trial designs, 
consequent packaging designs, and the need for randomization and blinding, and increased 
risk of product cross-contamination and mix up. Furthermore, there may be incomplete 
knowledge of the toxicity of the product and a lack of full process validation.  
On top of this, the logistics associated with the preparation and distribution of IMP to the 
sites also differs from a standard route as used in a commercial product. Here, the 
randomization and the systems in place to control such distribution, based on a site need in 
a defined point in time, are crucial to guarantee that the right medication is at the site place 
in the right time.  
Due to all of these challenges, moving from development to manufacture and to logistics, 
this project aim to make an overview about the development of an IMP, and the main 
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details that must be considered in the preparation, packaging, labeling and distribution of 
investigational medicinal products, in order to provide a quick reference tool in a 
professional and academic context. A review was made in the international literature to 
identify studies focusing on development and handling of IMP, mainly through PubMed 
and Medline databases, although it has also used guidelines, specialized books on the 
subject, and master and doctoral thesis. Only English language papers were selected, and 
whenever possible, the most recent articles were selected. 
This master thesis presents the main studies needed to be carried out during drug pre-
formulation, which will support the formulation stage. After formulation of the IMP in the 
convinient dosage form, preparation of IMP will be discussed in the next chapter, where 
concepts such as blinding, package and labeling will be of most interest. Subsequently, a 
brief discussion on the circuit of the IMP during the clinical trials will be reported. 
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CHAPTER	  2	  
Development	  of	  Investigational	  Medicinal	  Products	  	  
 
 
 
2.1.	  Pre-­‐formulation	  
 
The early stages of any new formulation include studies to collect basic information on the 
physical and chemical characteristics of the drug substance. These basic studies consist of 
pre-formulation work needed before product formulation begins.   
Pre-formulation study is the key to developing a successful formulation. Physicochemical 
characterization of a new drug substance should be performed regardless of its intended 
use. Upon identification of a lead candidate the drug discovery group needs to invest 
resources in identifying and synthesizing appropriate forms of drug candidate or 
candidates. Salt of the drug substance can significantly affect various properties such as 
solubility, bioavailability, and stability of the drug substance. Once a drug candidate is 
identified, an understanding of various physicochemical properties such aqueous solubility, 
pH solubility, pKa (dissociation constant), and log P (partition coefficient) is essential prior 
to initiating any formulation development activities [12].  
All IMP development is linked with chemical development, since this is where the 
development of a new chemical entity (NCE) starts. Furthermore, it is the mission of the 
chemists to ensure timely availability of NCE for use in other areas of development [13]. 
Some pharmaceutical companies have their own chemical development and production 
facilities, which greatly help, when in comparison with others that choose or are led to use 
outsourced manufacturing. In this last case, the transfer process becomes lengthy [13], but 
it would happen anyway in the development process unless the company has strong and 
industrial scale capabilities for manufacturing. When that is the case, a separate chemical 
development unit may be associated with the production plant [13]. 
Initial formulations for the majority of drugs are an injectable solution or dispersion for 
evaluation of basic pharmacology, bioavailability, pharmacokinetic and toxicology in 
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animals to confirm in vitro activity [14, 15]. However, approaches used during pre-clinical 
assessments may not be used when the drug is to be administered to humans, meaning that 
a more supported, detailed and extensive work need to be done when the scientists are 
working on developing a formulation to be used in a clinical trial. Here, all supportive 
information that can be gathered will help driving the development in the right path, 
avoiding steps back and forth and guiding not only formulation but also the establishment 
of the manufacturing process. 
It is crucial to obtain fundamental physicochemical, mechanical and physical information 
on the NCE, to ensure that potential formulation strategies are consistent with the 
chemistry of the molecule [15] and feasible on a practical perspective.  
There are several tests for a new drug molecule, but Wells consider two fundamental 
properties that are mandatory for a new compound: intrinsic solubility and dissociation 
constant (pKa) [15]. Others are, of course, of relevance and must also be determined, in 
support of the subsequent development steps. As well, and to allow the analytical control 
during development and the assessment of the formulation behavior, a simple analytical 
method must be developed [15]. The analytical pre-formulation includes:  
• Identification of the drug: tests such as nuclear magnetic resonance, infra red 
spectroscopy, ultraviolet spectroscopy (UV), thin-layer chromatography, 
differential scanning calorimetry and optical rotation [15];    
• Purity: moisture (water and solvents), inorganic solvents, heavy metals, organic 
impurities [15];  
• Assay: titration (usually Karl Fischer titration is the method in analytical chemistry 
used, which determine trace amounts of water in a sample), UV, high-performance 
liquid chromatography (HPLC) [15];  
• Quality: appearance, odour, solution colour, melting point and pH [15].  
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2.1.1.	  Solubility	  
	  
Two important factors in the entire development process are drug solubility and 
bioavailability [12].  
The time course of drug activity, drug blood levels, and levels in other body fluids will 
depend on a variety of factors including solubility and metabolism.  
In whatever way drugs are presented to the body, they must usually be in a molecularly 
dispersed form (that is in solution) before they can be absorbed across biological 
membranes [16]. The solubilisation process will precede absorption unless the drug is 
administered as a solution, but even solutions may precipitate in the stomach contents, and 
the precipitated will then have to re-dissolve before being absorbed [16]. 
Drug solubility is an important parameter for both oral and intravenous administration [12]. 
Oral intake is the most convenient and commonly employed route of drug delivery due to 
its ease of administration, high patient compliance, cost-effectiveness, least sterility 
constrains, and flexibility in the design of dosage form [17]. However, the major challenge 
with design of oral dosage forms lies with the poor bioavailability of most of the drugs. 
The oral bioavailability depends on several factors including aqueous solubility, drug 
permeability, dissolution rate, first-pass metabolism, pre-systemic metabolism, and 
susceptibility to efflux mechanisms. The most frequent causes of low oral bioavailability 
are attributed to poor solubility and low permeability [17].  
There are many factors controlling the solubility of drugs in solution, such as the nature of 
the drug molecule and the crystalline form in which it exists, its hydrophobicity, its shape, 
its surface area, its ionization state, the influence of the medium pH and the importance of 
the pKa of the drug [16, 18]. 
It is very important to know the molecule’s pKa in order to understand both 
physicochemical and bioavailability data. 
Various techniques are available for solubility determination of drug substance. The oldest 
and the most commonly used solubility measurement technique was developed by Higuchi 
and Connors [12], that consists in adding the drug substance to a small volume of the 
solvent (usually 2-4 mL). The mixture is then allowed to equilibrate by shaking or rotating 
at ambient temperature for a period of at least 24 hours or until undissolved particles are 
observed at the bottom of the vial/tube [12].  
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Although most researchers like to carry out the saturation solubility study at ambient 
temperature, some choose to perform the study at 37ºC, which will provide accurate 
prediction of in vivo solubility when the drug is travelling through the gastro-intestinal tract 
[12, 15], which can assist the formulator in designing a robust formulation [12].   
Nowadays, the NCEs under development are more intended for use as a solid dosage form 
and are also very poorly water soluble, fact that seems contradictory and, in fact, it is.  
Since some years ago, scientists started looking to this as an area of great development, 
since poorly water soluble drugs would theoretically, but in practice as well, originate bad 
absorptions and thus doubtful results in terms of pharmacokinetic parameters and in vivo 
interaction, e.g., with food. Also formulation challenges arose to bring scientists up to 
speed with the new information, techniques and know-how on solubility improvement. 
It became clear that it would be crucial to enhance solubility and, consequently, 
bioavailability of these drugs. Curiously, but expectably, the major current challenges of 
the pharmaceutical industry are related to strategies for improvement the solubility of drugs 
[19], and so it is of greater interest to consider the different approaches used to improve it 
(table 1). 
The techniques are chosen on the basis of certain aspects such as properties of the drug 
under consideration, nature of excipients to be selected, and nature of intended dosage form 
[17].  
	  
	  
Table 1. Techniques for Solubility Enhancement of Poorly Soluble Water Drugs 
Physical Modifications Chemical Modifications Miscellaneous Methods 
Particle size distribution Change of pH Supercritical fluid process 
Modification of crystal format Complexation Use of adjuvant 
Solid dispersions Salt formation Hydrotrophy 
Cryogenic techniques   
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In summary, solubility of the active pharmaceutical ingredient (API) is a crucial attribute 
with respect to [20]:  
• Selecting the dosage forms for clinical trials;  
• Designing experiments to identify potential salt forms, cocrystal forms, 
polymorphic forms, solvates and hydrates; 
• Aiding drug-manufacturing strategies.  
 
 
 
2.1.1.1.	  Physical	  Modifications	  
	   2.1.1.1.1.	  Particle	  Size	  Distribution	  	  
	  
A critical quality criterion for the solubility is the particle size distribution (PSD). 
Especially for poorly water soluble drugs the PSD is one of the characteristics that must be 
controlled, and usually leads to the establishment of a quality specification as part of the 
general quality control of the product. Techniques such as laser diffraction, using either 
Mie or Fraunhofer theory and optical microscopy (when the first cannot be used due to the 
shape of the particles or due to difficulties during method development) can be used to 
determine the PSD and can be complemented by a surface area determination [19].  
Decreasing the particle size, leads to a surface area increase, resulting in a potentially 
increased dissolution rate, thus solubilisation, and, consequently, improved bioavailability. 
Reducing particle size is primarily done by milling or micronization, which consists in 
reducing particle size to a minimum in order to improve wettability, and, for consequence, 
bioavailability [19]. At this point, dissolution curves for different particle sizes can be 
made to verify what sizes have direct impact in dissolution and for which ranges the 
dissolution will be similar.  
Apart from solubility, the particle size may also influence the uniformity of dosage of very 
potent drugs used in considerably small amounts and formulated as a solid dosage form 
[16]. Another example where particle size is of importance relates to direct absorption, for 
instance, in pulmonary delivery where only very fine particles are able to penetrate the 
alveolar regions of the respiratory tract [16]. However, if the particle size is reduced too 
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far, particles may be exhaled and not deposit [16], resulting in less absorption extent and 
thus potential lack of efficacy due to dose loss.  
Particle size also has important effects on the bulk properties of a powder flow during 
manufacturing processing when large quantities of material are handled. It is important that 
pharmaceutical powders are able to flow freely into storage containers or hoppers of tablet 
and capsule-filling equipment so that a uniform packing of the particles and hence a 
uniform tablet or capsule weight is achieved [16].  
Despite being a fast method to improve solubility, micronization also has several 
disadvantages related to the limited opportunity of control important characteristics of the 
final particle such as size, shape, morphology, surface properties and electrostatic charges 
[21]. 
It becomes important to refer to the nanosuspension as a particle size reduction technique, 
since the major problems of the other techniques is lack of universal applicability to all 
drugs [22]. Over the last decades, nanoparticle engineering has been developed and 
reported for pharmaceutical applications [22, 23], enhancing solubility of drugs that are 
poorly soluble in water [24]. As a result of increased solubility, the rate of flooding of the 
active compound increases and the maximum plasma level is reached faster.  
 
 2.1.1.1.2.	  Modification	  of	  Crystal	  Format	  
	  
Often for drugs with very low aqueous solubility, the achieved increase in dissolution rate 
is insufficient to provide adequate enhancement of bioavailability. The potential for 
increased Van der Waals interactions and electrostatic attraction between ultrafine particles 
can also act to reduce the effective surface area for dissolution and therefore limit 
improvements in bioavailability [25]. Crystal engineering approaches, which can 
potentially be applied to a wide range of crystalline materials, offer an alternative method 
for improving the solubility, dissolution rate and subsequent bioavailability of poorly 
soluble drugs. The ability to engineer materials with suitable dissolution characteristics, 
maintaining suitable physical and chemical stability, provides a strong driver for the use of 
new and existing crystal engineering approaches to drug delivery system design [25]. 
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Crystallization is concerned with the evolution from solution or melt of the crystalline 
state. Within this area, key issues include the formation of crystal nuclei, the influence of 
crystallization conditions, and the overlap between the concepts of the growth unit, and an 
understanding of how the overall shape of a crystal evolves [25]. 
Once nucleation has been achieved, crystal growth leads to the evolution of embryonic 
crystals into a crystal form of defined size and shape. The key drivers with regard to the 
shape of the growing crystal are related to the crystal lattice of the molecular solids and the 
effects of the choice of solvent and additives on the process of crystal growth. As such, 
crystal growth is a layer-by-layer process, with the evolution of the layers being defined by 
the crystal packing of the unit cell. The unit cell in turn describes the critical elements of 
how a specific molecular species has assembled in a crystalline state in three dimensions 
[25]. 
The crystal morphology depends on the conditions of crystallization and may affect the 
syringeability of suspensions of the drug, its ease of compression into tablets and its flow 
properties [16]. The crystal formats can be modified generally by adding surfactants to the 
solvent used for crystallization [16].  
Knowing that the amorphous form of a chemical substance is usually more soluble than the 
crystalline form, different extents of drug absorption may result from here with consequent 
differences in the degree of pharmacological activity. Most of the developed drugs are 
present in a crystalline form and not in its amorphous form. This drives scientists in 
looking for other alternative approaches, which also includes changing the substance to its 
amorphous form (topic 2.1.1.1.3.). 
However, crystalline forms of drugs may be used because of greater stability than 
corresponding amorphous forms [21]. Also, the various polymorphic forms can differ in 
drug action (pharmaceutically and therapeutically) because they differ in many physical 
properties [21]. 
By manipulating the crystallization conditions it is possible to prepare crystals with 
different packaging arrangement: such crystals are called polymorphs [17]. As a result, the 
majority of drugs can crystallize into several polymorphs. Each polymorph has a different 
energy, showing different physicochemical properties, such as melting point, density, 
solubility, dissolution rate and stability [26]. Generally, the solubility of metastable 
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polymorphs is kinetically higher than that of a thermodynamically more stable polymorph 
[17, 26].   
 
 2.1.1.1.3.	  Solid	  Dispersions	   
 
Over the past few years, interest has been shown in solid solutions of drugs in attempts to 
change the biopharmaceutical properties of drugs that are poorly soluble or difficult to wet. 
The main goal is usually to provide a system in which the crystallinity of the drug is 
changed to increase its solubility and dissolution rate, and to surround the drug intimately 
with water soluble material [16]. This approach has a tremendous potential and the 
literature reviews of the past four decades of research suggest that there is an increasing 
interest in using it [21]. 
Solid dispersions represent a useful pharmaceutical technique for increasing the 
dissolution, absorption, and therapeutic efficacy of drugs in a specific dosage form [17]. 
The term solid dispersion refers to a group of solid products consisting of at least two 
different components, generally a hydrophilic matrix and a hydrophobic drug [17].  
Vasconcelos [19] described three solid dispersions generations. The first generation was 
prepared using crystalline carriers, such as urea and sugars, that produced higher 
bioavailability, but it have the disadvantage of forming crystalline solid dispersions, which 
were thermodynamically more stable and did not release the drug as quickly as the 
amorphous ones [19]. Then, a second generation of solid dispersions appeared, which 
contained amorphous carriers instead of crystalline. Polymeric carriers have been the most 
successful for solid dispersions, because they are able to originate amorphous solid 
dispersions [19]. In amorphous solid solutions, drug and carrier are totally miscible and 
soluble, originating a homogeneous molecular interaction between them, resulting in a 
really true solution [19]. On the other hand, drugs with a high melting point and/or limited 
carrier solubility are candidates for producing an amorphous solid suspension [19]. 
Recently, third generation solid dispersions appeared which contains a carrier or a mixture 
of amorphous polymers and surfactants. This last generation is intended to achieve the 
highest degree of bioavailability for poorly soluble drugs and to stabilize the solid 
dispersion, avoiding drug recrystallization [19]. The use of surfactants as carriers was 
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shown to be effective in originating high polymorphic purity and enhanced in vivo 
bioavailability. In addition, the use of surfactants may help to prevent precipitation and/or 
protect a fine crystalline precipitate from agglomeration into much larger hydrophobic 
particles [19].  
Solid dispersions are easier to produce and the application is now wider than the salt 
formation. Furthermore, solid dispersions are more acceptable to patients, since they give 
rise to solid oral dosage forms instead of liquid ones [19].  
In summary, it is possible to conclude that crystalline substances are more stable than 
amorphous substances, but the amorphous ones are more soluble. The increase in 
dissolution rate for solid dispersion can be attributed to a number of factors, such as 
reduced particle size or reduced agglomeration [21]; a possible solubilisation effect by the 
carrier, which may operate in the diffusion layer [16]; improved wettability in the intimate 
drug-carrier mixture [16], transferring the drug from a crystalline to amorphous state [21], 
more soluble, among others factors.  
 
 
 
2.1.1.1.4.	  Cryogenic	  Techniques	  
	  
Cryogenic techniques have been developed to enhance the dissolution rate of drugs by 
creating, at very low temperature conditions, nanostrutured amorphous drugs particles with 
high degree of porosity [17].  
Cryogenic inventions can be defined by the type of injection device (capillary, rotary, 
pneumatic and ultrasonic nozzle), location of nozzle (above or under the liquid level), and 
the composition of cryogenic liquid (hydrofluoroalkanes, N2, Ar, O2 and organic solvents) 
[17].  
After cryogenic processing, dry powder can be obtained by various drying processes like 
spray freeze drying, atmospheric freeze drying, vacuum freeze drying, and lyophilisation 
[27].  
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2.1.1.2.	  Chemical	  Modifications	  
	   2.1.1.2.1.	  Change	  of	  pH	  
	  
Another technique is the adjustment of the pH of the solvent to enhance solubility. 
However, for many drug substances pH adjustment is not an effective means of improving 
solubility [28]. 
The effect of pH on solubility is critical in the formulation of liquid dosage forms, from 
oral and topical solutions to intravenous solutions. The solubility of a weak acid or base is 
often pH dependent. However, weak acidic or basic drugs may require extremes in pH that 
are outside accepted stability ranges. In many cases, it is desirable to use co-solvents or 
other techniques such as complexation, micronization, or solid dispersion to improve 
aqueous solubility [28].  
Modifications of pH in solid dosage forms is considered to be an alternative option for an 
ionizable drug in order to improve the solubility and dissolution rate. The incorporation of 
pH modifiers in the dosage form can alter the micro-environmental pH. Micro-environment 
is a term used to represent a microscopic layer surrounding a solid particle in which the 
solid forms a saturated solution of adsorbed water [29]. The micro-environmental pH 
would affect the performance of the solid dosage form, such as the chemical stability of the 
drug substance and the dissolution profile [30]. There have been several studies 
demonstrating the pH-independent release of basic drugs form controlled release dosage 
forms by using pH modification technologies [26].  
To obtain the complete dissolution of the drug from dosage form, the pH modifier may 
need to coexist with the drug particles in tablet or granule until the containing drug is 
completely dissolved. Accordingly, the excipients and manufacturing methods would 
affect the dissolution performance of the drug from the pH-modified solid dosage forms. 
The estimation of the micro-environmental pH in the dosage form is thought to be helpful 
in designing pH-modified dosage forms [26]. 
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2.1.1.2.2.	  Complexation	  	  
	  
Among all the solubility improvement techniques, inclusion complex formation technique 
has been employed more precisely to enhance the aqueous solubility, dissolution rate and, 
consequently, bioavailability of poorly water soluble drugs [17]. 
Inclusion complexes are formed by insertion of the nonpolar molecule or the nonpolar 
region of one molecule (known as guest) into the cavity of another molecule or group of 
molecules (known as host). The most commonly used host molecules are cyclodextrins 
(CD) [17].  
CDs occur naturally and are obtained through the enzymatic reaction on the starch [16] 
[31]. CDs are cyclic oligosaccharides built up from glucopyranose units linked by α-1,4 
bonds, thus forming a torus-like macro-ring [16, 31]. They are characterized as crystalline, 
water-soluble, homogenous, and non-hygroscopic substances, and they may modify 
important properties of the drugs through their inclusion complex formation ability [17, 
31].  
CD molecules surface gives them water-soluble properties, but the hydrophobic cavity 
creates a micro-environment for non-polar molecules. Based on the intrinsic properties of 
the molecule, such as its structure, drug-CD complexes can be generated in 1:1 or 1:2 
proportions as illustrated in figure 1.  
 
 
 
 
 
 
	  	  
Figure 1. 1:1 and 1:2 Drug-Cyclodextrin Complexes. Adapted from Davis and Brewster (2004) 
[32]	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2.1.1.2.4.	  Salt	  Formation	   	  
	  
The majority of NCE do not have water solubility since they are organic molecules of low 
molecular weight, generally, weak acids or weak bases, and therefore salts may be required 
[14]. One of the major improvements in solubility can be achieved by forming a salt, and 
this is the most preferred approach for the development of liquid formulations for 
parenteral administration [18].  
The dissociation constant (pKa) of the parent molecule must be known prior to the 
selection of the salt and, generally, this selection is determined from a shortened list of 
potential pharmaceutical acceptable counter ions [33].  
In case of strong acids or strong bases, salts prepared are freely soluble but very 
hygroscopic, leading to instability in tablet or capsule formulations. Therefore, weak acid 
or base solutions are preferred even though they have less solubility, but are also less 
hygroscopic.  
During the salt selection process, attempts are generally made to minimize the potential for 
multiple forms of drug. So, consideration for the proper crystal modification to be 
developed for clinical evaluation should occur early in the development [33]. In fact, this is 
one of the major concerns: some drugs can crystallize in more than one polymorphic form 
characterized by differences of packaging in the crystal lattice or in the orientation or 
conformation of the molecules at the lattice sites [16]. Polymorphs of the same drug may 
have different melting points and solubility, and usually exist in different habits [16]. 
Polymorphs may cause problems in the formulation, analysis and, especially, 
bioavailability of drugs. The development of specific polymorphs is in disuse, and the trend 
is the drug modifications using new drug delivery systems, consisting in the modification 
of the API’s structure to originate intrinsic characteristics that improves solubility, and, for 
consequence, keeping the stability of the drug.  
Furthermore, processes involved in manufacturing, such as grinding, granulation, 
compression, or mixing, can also affect and originate changes in crystal form [33]. To 
avoid these problems, screening for crystal modifications should be completed before 
initiation of preclinical safety assessment studies that will support clinical development 
[33]. This evaluation can be effected, for example, altering recrystallization solvents and 
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temperatures, exposing purified drug substance to varying humidity conditions, and 
performing compaction stressing of the drug substance [33]. 
Salts are usually prepared from organic solvents and they are destined to encounter 
aqueous environment (water, humidity) during dosage form development, and at the time 
of dissolution in gastrointestinal fluid, in case of an orally administered tablet or capsule. 
This can be a major issue and its use may be limited, since a perfectly good salt isolated 
from an organic solvent may not behave well in an aqueous environment due to low 
solubility, conversion to free acid or base forms and poor stability [18]. 
 
 
 
2.1.1.3.	  Miscellaneous	  Methods	  
	  2.1.1.3.1.	  Supercritical	  Fluid	  Process	  
	  
Another novel nanosizing and solubilisation technology, whose application has increased 
in recent years, is particle size reduction via supercritical fluid (SCF) processes. According 
to Savjani et al. [17], SCF are fluids whose temperature and pressure are greater than its 
critical temperature (Tc) and critical pressure (Tp), allowing it to assume the properties of 
both a liquid and a gas. At near-critical temperatures, SCFs, are highly compressible 
allowing moderate changes in pressure to greatly alter the density and mass transport 
characteristics of the fluid that largely determine its solvent power [17, 34]. Thus, reducing 
the particle size, solubility increases. 
	  
	   2.1.1.3.2.	  Use	  of	  Adjuvants	  
	  
The use of surfactants improves the dissolution performance of poorly soluble drug 
products, and is probably the basic, primary, and oldest method applied. The surfactants 
reduce surface tension and improve the dissolution of lipophilic drugs in aqueous medium, 
but they are also used to stabilize drug suspensions [17].  
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When the concentration of surfactants exceeds their critical micelle concentration (which is 
in the range of 0.05-0.10% for most surfactants), micelle formation occurs which entrap the 
drugs within the micelles. This is known as micellization and generally results in enhanced 
solubility of poorly soluble drugs [17, 35].  
Surfactant also improves wetting of solids and increases the rate of disintegration of solid 
into finer particles. Furthermore, surfactants are often used to stabilize microemulsions and 
suspensions into which drugs are dissolved [35].     
	  
	  
	  2.1.1.3.3.	  Hydrotrophy	  
 
Hydrotrophy is a solubilisation process, which consists in an addition of a large amount of 
second solute, the hydrotropic agent, resulting in an increase in the aqueous solubility of 
first solute. So, the hydrotrophy designates the water solubility increase due to the presence 
of large amount of additives. The mechanism by which it improves solubility is more 
closely related to complexation, involving a weak interaction between the hydrotropic 
agents, like sodium benzoate, sodium acetate, sodium alginate, urea, and the poorly soluble 
drugs [17].  
 
 
 
2.1.2.	  Partition	  Coefficient	  
	  	  
Partition coefficient (Log P) is a key property in determining hydrophilic or lipophilic 
characteristics of the NCE [12], and it is defined as the ratio of concentrations of the 
substance in oil and in water. With the advent of the high-throughput screening, a 
technique that allows the screening of thousands of new compounds in a very short period 
of time, several molecules identified in very early stage are lipophilic, with large molecular 
weight and, therefore, cause serious challenges due to their solubility and permeability 
limitations [12, 36]. 
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Partition coefficient is also a good indicator of diffusion or permeation across the cell 
membrane, which is the rate-limiting step in the drug transport process [12]. 
 
 
 
2.1.3.	  Dissociation	  Constant	  (pKa)	  
	  
Dissociation refers a process in which the compound is separated into smaller ions or 
particles. The portion of the drug dissociated can be represented by the dissociation 
constant (pKa), also known as ionization constant. Ionization plays an important role in 
determining the permeability of the drug molecule across various physicochemical 
membranes [12].  
Dissociation constant, or pKa, is usually determined by potentiometric titration. However, 
for this method to be effective the drug must be at least slightly soluble in aqueous media 
[12, 28]. 
Nowadays, high-throughput techniques are available for measuring ionization constant, 
such as the most recent: capillary electrophoresis (CE) [37]. The CE technique offers 
advantages over traditional techniques because uses much less sample than other 
techniques available [37]. Moreover, because it is based on an analytical separation 
technique, several substances can be measured simultaneously. The basis for determination 
of dissociation constants by CE is measurements of the migration time of the analyte in 
electrolytes with a well-defined pH. In practice, the mobility is calculated from the 
migration time for the analyte as well as for the electro-osmotic flow [37]. Several studies 
have demonstrated the use of CE applicated to pKa, and some authors have suggested the 
use of CE for unstable compounds in aqueous solutions [37]. A challenge can be raised 
when analyzing labile compounds, but Ornskov et al. showed that pKa can be determined 
with high precision and accuracy also for labile drug compounds using CE [37]. 
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2.1.4.	  Membrane	  Permeability	  
	  
Due to poor physicochemical properties of drug substance, the ultimate aim of the drug 
development process is to increase the cell-membrane permeability, and to achieve 
significant intestinal absorption. Also, regardless of the route of administration, cell 
membrane permeation is required for a drug molecule to reach the general circulation [12].  
Modern pre-formulation studies include an early assessment of passage of drug molecules 
across biologic membranes, and such permeability studies play a key role in determining 
the formulation strategy [12, 28].  
Data obtained from the basic physicochemical studies, specially, pKa, solubility, and 
dissolution rate, provide an indirect indication of absorption [28]. However, a reliable 
screening method is required to assess the permeability of the drug. Various in vitro models 
are available for the prediction of membrane permeability. The major advantage of 
artificial membrane permeability over biological preparations are reproducibility, whereas, 
the major limitations are lack of enzymes, transporters, and paracellular pathways [38].        
 
 
 
2.1.5.	  Chemical	  Stability	  
	  
Many drugs are susceptible to some form of chemical decomposition when formulated in 
their liquid or even solid dosage forms. Figure 2 shows some of the factors that influence in 
drug stability according to pharmaceutical dosage forms. 
Chemical degradation of the active drug can lead to a substantial lowering of the quantity 
of the active moiety in the dosage form. Furthermore, the low therapeutic efficacy can also 
result as a consequence of physical and chemical changes in the excipients present in the 
dosage form [16]. Although chemical degradation of the API may not be extensive, a toxic 
product may be formed in the decomposition process, causing undesirable effects [16].    
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Figure 2. Examples of Factors Influencing Drug Stability of Liquid and Solid Dosage Forms 
 
The chemical stability studies conducted on solid dosage forms under a range of different 
storage conditions and over different periods of time, aim to evaluate the chemical 
degradation at a range of various temperatures (depending upon stability), variable levels 
of relative humidity up to 90% [14, 39] and exposure to artificial or natural light 
(photostability), and in the presence of oxygen [40]. These studies can also be conducted 
on aqueous solutions at various pHs and temperatures and in a variety of solvents [14].   
The primary cause of degradation of APIs in aqueous systems is hydrolysis1 and the most 
susceptible drugs are those containing ester, amide, lactone, lactam, imide or carbamate 
groups. The inclusion into the formulation of non-aqueous solvents may, in some cases, 
reduce hydrolysis by alteration of the dielectric constant [16].  
The second most common cause of drug breakdown is oxidation2. Oxidative degradation 
represents a problem with drugs possessing carbon-carbon double bonds such as steroids, 
polyinsaturated fatty acids and polyene antibiotics [16].  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Hydrolytic	  breakdown	  is	  catalysed	  by	  hydrogen	  and/or	  hydroxyl	  ions	  and,	  consequently,	  formulating	  the	  
product	  at	  the	  pH	  of	  maximum	  stability	  may	  reduce	  the	  extent	  of	  hydrolysis.	  
2	  Oxidative	  degradation	  can	  occur	  by	  autoxidation,	  in	  which	  the	  reaction	  is	  uncatalysed	  and	  proceeds	  quite	  
slowly	  under	  the	  influence	  of	  molecular	  oxygen,	  or	  may	  involve	  chain	  processes	  consisting	  of	  three	  
concurrent	  reactions:	  initiation;	  propagation	  and	  termination.	  
Factores	  influencing	  drug	  
stability	  
Liquid	  dosage	  forms	  
pH,	  temperature,	  ionic	  
strengh,	  solvent	  
effects,	  oxygen,	  light,	  
surfactants	  
Solid	  dosage	  forms	  
Moistures,	  excipients,	  
temperature,	  light,	  oxygen	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Photochemical decomposition has been also considered an important cause of degradation, 
which can be a serious problem that can cause discoloration and loss of therapeutic activity 
of the drug. Photodecomposition might occur, not only during storage, but also during the 
handling of the product. Formulations containing light-sensitive drugs have to be stored in 
appropriate opaque or coloured containers, which either remove the ultraviolet components 
of light [16] or avoid light to pass through.  
The forced degradation studies, performed during development to support subsequent steps 
in drug development, indicates how the drug should potentially degrade and also provide 
information for manufacturing process and packaging requirements. For example, if the 
drug is rapidly oxidized, the formulator can add certain excipients or change the 
manufacturing or packaging processes to minimize this degradation pathway [40]. The 
methods used along pre-formulation studies, needs to be adjusted to resolve new 
degradation processes involving products or excipient-related components [33].  
Stability studies will give the feasibility of various types of formulation and packaging, 
being fundamental in following steps of drug development [14].    
 
 
 
2.1.6.	  Excipient	  Compatibility	  
	  
An excipient is defined as a material that is deliberately incorporated into the formulation 
to aid in a part of the process, increase the process feasibility or, simply, to improve the 
aspect or taste of the pharmaceutical form. Thus, excipients can improve tablet integrity, 
dissolution, bioavailability, or taste, amongst other characteristics. Moreover, excipients 
can also assist in modifying or permitting drug delivery [2] and can also improve stability 
of the API [40].  
A successful formulation depends on the careful selection of excipients, which should not 
interact with the drug substance, or any other excipient.   
Before formulation starts, studies to choose the excipients should be performed, with the 
aim to study drug-excipient and excipient-excipient mixtures, using differential scanning 
calorimetry at typical processing temperatures, which requires small samples of API. No 
interaction indicates potential stability [14], but, additionally, another studies are useful for 
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early identification of any potential excipient-excipient interactions that can confuse 
analyses [33, 40]. There are several sources of information on excipients used in approved 
drug products [33, 40].  
In summary, pre-formulation testing provides a basic dossier on the compound and plays 
an important role in identifying possible problems and suitable approaches to formulation 
[14]. However, some pre-formulation studies may need to be repeated during the 
development process when changes to the API or its manufacturing procedure occurs [40]. 
During all the formulation development it is important to be aware that some excipients 
may alter the pharmacokinetics of a given drug [2]. 
 
 
2.2.	  Formulation	  
	  
Only correct formulation can turn a new API into a safe and ready-to-use drug, that can be 
dosed as required. Formulation scientists work to ensure that the body can absorb the 
substance and the therapeutic dose reaches the targeted organ. Not every drug is suitable 
for ingestion as a standard tablet, and special demands on the form of administration – 
injection into the eye, products for inhalation, or orodispersible tablets that dissolve quickly 
in the patient's mouth “without water” – regularly create new challenges for formulation 
scientists. 
Formulation can be defined as an experimental stage in drug development to set a physical 
system that can be used, keeping in mind process feasibility, quality of the product and 
stability. The transformation of a drug into a medicinal product is a complex process that is 
controlled by a range of competing factors [14], such as patient acceptance and specific 
requirements of the API.  
It is important to consider certain principles of the formulation, especially with focus on 
clinical trials environment [39]:  
• A suitable formulation permits the conduct of clinical trials, mainly 
because it strongly influence patient acceptability;   
• Formulations constrain clinical trial design. For example, 
bioavailability must be reconciled with toxicology coverage, well-
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matched placebos may or may not be available, and special procedures 
may be required;   
• Product storage and stability (or lack thereof) can bias the results of 
clinical trials. 
The choice of formulation will significantly impact other parameters, such as efficacy, 
safety, manufacturing, and, obviously, the cost. Pharmaceutical scientists work closely with 
discovery scientists, clinical operations staff, manufacturing scientists and regulatory 
managers to devise the best possible formulation for patients at a reasonable cost for the 
company [40]. It should be noted, however, that formulation costs tend to decrease from 
development to commercial due to scale savings. The batch scales used throughout 
development and to commercialization of a product present differences, sometimes 
significant, thus impacting the global costs on an unit basis.   
Many characteristics studied in early development such as solubility, stability, safety, 
potency, half-life, and molecular size will strongly influence the product profile [40] and 
must be considered when formulating.   
Further, it s important to keep in mind that a medicine is not just an active compound, but 
also includes excipients, degradants of the active compound, degradants of the impurities 
and those from excipients [39], that must be considered during formulation, so that all 
knowledge must support analytical development for future control of the developed 
product. Impurities and degradants can have their own toxic potential, so is important to 
control impurity content in early development. But, most of times, the structures of these 
impurities and degradants may not be well characterized, being typically common both 
bulk drug and finished product to become more refined as clinical development proceeds 
[39]. It is common practice, and also a safe measure, to use “less pure” bulk drug for 
toxicology studies, in order to restrain any new toxicology problems developing later 
during clinical research [39]. Then, as the clinical program develops, batches tend to be 
more and more pure, most of the times due to changes and adaptations in the synthetic 
routes of the API or in the manufacturing process itself. 
All data from pre-formulation studies and preclinical studies are crucial to choose a 
particular route of administration [41]. Since, the formulation must also be suitable for 
rapid and economical manufacture [14], commonly, pharmaceutical companies prefer to 
develop an oral dosage form, in most cases a solid one. Dosage forms associated with oral 
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administration are relatively cheap to manufacture, are simpler for patients to handle, and 
are widely accepted by the public [33]. Because of these facts it becomes critical to 
evaluate the oral bioavailability of candidate compounds in the early stages of 
development.  
Bioavailability is a term that describes the pharmacokinetic “speed” and extent to which an 
active compound or its active moiety is released from a drug product, absorbed by the 
human body and becomes available at the site of action. The assessment of bioavailability 
is performed based on pharmacokinetic parameters calculated from the plasma 
concentration profiles of the drug over time. The bioavailability studies allow not only to 
assess the quality of medicine, based on its pharmacokinetic profile, but also to evaluate 
drug interactions and the influence of various physiological and pathological factors (age, 
diet disease, especially renal and hepatic function, etc.) in the drug absorption.  
Understanding oral bioavailability of a compound provides a significant insight of the 
strategy of the formulation development [33]. As already discussed, some formulation can 
significantly improve bioavailability, predominantly if the reason for the poor 
bioavailability is related to the drug’s solubility [40]. If preclinical studies indicate an 
acceptable bioavailability of the molecule, then the best approach is to dose orally using a 
simple dosage form, such as solutions or encapsulated drug substance [33].  
A classification system was developed to relate drug intestinal absorption to the physical 
properties of drugs (such solubility), in which drugs are classified in four classes (table 2). 
	  
	  
Table 2. The four Biophamaceutical Classification System (BCS). Adapted from Florence and 
Attwood (2011) [42] 
The four Biophamaceutical Classification System (BCS) 
Class I: High solubility, high permeability Class II: Low solubility, high permeability 
 
Class III: High solubility, low permeability Class IV: Low solubility, low permeability 
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2.2.1.	  Bioavailability	  and	  Bioequivalence	  
	  
As mention above, bioavailability is a term that describes the pharmacokinetic speed and 
extent to which an active compound, or its active moiety, is absorbed from a drug product 
and becomes available at the site of action. Considering the various stages through which a 
drug substance is intended to be absorbed in the body, a series of phenomena are referred 
to by the acronym (R)ADME, which means: (release), absorption, distribution, metabolism 
and excretion.  
The “release” is referred as the stage that most affect the bioavailability [43]. There are 
many attempts to overcome the obstacles that block a proper absorption, being common the 
use of pro-drugs that cross better semi-permeable membranes, than the drug itself [43]. 
Thus, bioavailability between 80 or 100 per cent is not an easy task, especially considering 
a whole load of excipients and adjuvants, which is necessary to add.  
Both the rate and extent of drug absorption can be substantially modified by formulation 
and processing variables: if there is any significant change in the formulation or process 
during the clinical trials development period, the questions of bioequivalence needs to be 
addressed [44].   
The purpose of a development bioequivalence study is to build a bridge between a product 
used in clinical trials with a version that will actually be marketed [44] or eventually used 
in a different phase of the clinical development program.  Thus, whenever a new dosage 
form of the drug is developed, it must demonstrate that it is bioequivalent with respect to 
the original form to establish the safety and efficacy of the drug. Also, when a formulation 
has been used in clinical trials and another separate formulation is selected for the product 
to be marketed, a bioequivalence test will be need [44]. 
 
 
2.2.1.1.	  Factors	  Affecting	  Bioavailability	  
	  
Bioavailability of a drug depends upon pharmaceutical factors related to physicochemical 
properties of the drug and characteristics of the dosage form, pathophysiology of the 
disease, and route of administration [45]. Table 3 shows the major factors that affect 
bioavailability. 
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Two major problems can be identified that result in poor bioavailability of an orally 
administered drug [45]:  
• Degradation of the drug into inactive form; 
• Interaction with one or more components of the dosage form or those present in 
the gastro-intestinal tract to form a complex that is poorly soluble or is 
unabsorbable.  
 
 
Table 3. Factors Affecting Bioavailability 
Factors affecting Bioavailability 
Physicochemical 
Properties of the Drug 
Substance 
Physiological Factors 
Physicochemical 
Interactions in Dosage 
Form 
Polymorphism 
Gastrointestinal 
motility 
Drug-excipient 
interactions 
Salt Form Gastric Emptying 
Excipient-excipient 
interactions 
Pro-drug Intestinal Transit Rate 
Effect of excipients on 
physiological processes 
 Food and pH Effect 
Modification of 
Biorelevant Drug 
Product Properties by 
excipients 
 Window of Absorption  
 
Variability in 
Metabolizing Enzymes 
and Efflux Transporters 
 
 
 
Concerning physiological factors, gastric emptying provides greatest influence on the rate 
of oral drug absorption, since an orally administered dosage form encounters the stomach 
first. Also, gastric muscles exert mechanical pressure on the dosage form. Gastro-intestinal 
transit times can influence oral drug bioavailability through a multitude of mechanisms, 
such:  
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• Gastric empty: for the drugs administered as solid particles or tablets, rapid 
gastric emptying can lead to incomplete drug dissolution in the stomach, 
which can further reduce the extent of drug absorption [45].   
• Intestinal Transit Rate: general increases in intestinal motility can increase 
the rate of drug transport from one intestinal segment to the next. Several 
factors can affect gastro-intestinal motility, such as pharmacological effect 
of the drug itself [45].    
• Food and pH Effect: food intake can affect drug absorption either by 
directly interacting with the dosage form or by affecting gastro-intestinal 
physiological parameters relevant to drug absorption. Food also influences 
gastric pH: while the normal gastric pH is 1-3 in fasted state, the fed state 
gastric pH in humans can be 4.3-5.4 [46]. The effect of gastric pH on oral 
drug absorption can be most predominant for weakly basic compounds that 
have high solubility at acidic pH in the stomach and low solubility at the 
basic pH in the intestines. The rate and extent of oral bioavailability of these 
drugs in humans is dependent on their rapid dissolution from an oral solid 
dosage form in the acidic stomach [45].  
• Absorption window: some drugs are only soluble at a particular pH or they 
are absorbed using a specific mechanism. These drugs can only be absorbed 
in specific segments of the gastro-intestinal tract. Those particular segments 
are named "absorption windows" [45].  
• Variability in metabolizing enzymes and efflux transporters: several drugs 
are substrates of the drug metabolizing enzymes in the gastro-intestinal tract, 
such as cytochrome P450 (CYP) enzymes in the intestinal mucosa, and 
efflux transporters, such as the P-glycoprotein (P-gp) family of transporters. 
Oral absorption of drugs that are substrates of the efflux transporters and 
metabolizing enzymes is understandably affected by the inter-individual 
expression level and intra-individual distribution of these proteins in the 
gastro-intestinal tract. For example, P-gp transport has been linked to the 
low and variable oral bioavailability of several compounds [47]. In addition, 
drugs whose absorption is affected by transporters and metabolizing 
enzymes can also be sensitive to certain food effects [48].   
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Excipients can also affect drug bioavailability through physicochemical interactions in the 
dosage form that can affect drug absorption. Such interactions could be drug-excipient or 
excipient-excipient interactions [45]. The most common interactions regarding excipients 
are drug-excipient interactions [49]. Drug-excipient interactions can be a result of physical 
(polymorphism, crystallization), chemical (oxidation, hydrolysis) or biopharmaceutical 
interactions. Excipients can initiate, propagate or participate in physical or chemical 
interaction with drugs, affecting the therapeutic efficacy of the drugs.  Thus, interactions in 
solid dosage forms between its components and of its components with the physiological 
processes can affect the bioavailability of drugs. Understanding these phenomena is crucial 
to avoid their undesired consequences [45].  
Since excipients can interact directly with physiological processes, such as pH of gastro-
intestinal fluids in the immediate vicinity of the dosage form, gastro-intestinal transit time, 
effective membrane permeability, drug degradation in the gastro-intestinal fluids and drug 
metabolism and efflux during absorption, they can alter the rate and extent of drug 
absorption [45]. The effect of excipients on gastro-intestinal motility is dependent on their 
concentration, and can influence drug absorption. This effect can be avoid or minimized by 
lowering its concentration in the formulation [45].   
 
 
	  
2.2.2.	  Dissolution	  Testing	  	  
	  
Laboratory tests to measure physical properties in vitro can give insights into the quality of 
the product. One of the common tests applied to oral dosage forms, in particular, is the 
measurement of drug rate of release by using dissolution test.  
In the pharmaceutical environment, dissolution testing is an important tool in drug 
development and quality control. Although initially developed for immediate release solid 
oral dosage forms, and then for modified release solid oral dosage forms, the application of 
dissolution testing has expanded to a variety of another dosage forms. As these 
formulations have become more prevalent due to complexities of drug delivery, there has 
been an increased development of modified testing methods to characterize the in vitro 
release of these dosage forms [50].  
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For orally administered immediate release solid drug products, it is common to refer to the 
test as a “dissolution” test, since the intention is to dissolve the drug in the test medium. 
However, for non-oral dosage forms, such as topical and transdermal delivery systems, 
suppositories, and others, the test is referred to preferably as a “drug release” or “in vitro 
release” test procedure. As special dosage forms exhibit significant differences in 
formulation design, which in turn leads to very different physicochemical and release 
characteristics, it is not possible to devise a single test system to study the drug release 
properties. Rather, different apparatus, procedures, and techniques are employed on a case-
by-case basis, and the method may be specific to the dosage form category, formulation 
type, or even to a particular individual product [50]. 
Since most of the investigational medicinal products are intended for solid oral dosage 
form, this topic will give more importance to that dosage forms. 
First, it is necessary to define dissolution and dissolution testing. Dissolution is the process 
of extracting the drug substance out of it dosage form into solution within the 
gastrointestinal tract [51]. As described before, absorption is the process of transporting the 
drug substance from the gastrointestinal tract into the systemic circulation. So, dissolution 
testing is an in vitro method designed to demonstrate how efficiently an active drug 
substance is extracted out of a solid oral dosage form [51, 52]. Figure 3 shows, 
schematically, the relationship between dissolution test and absorption of a drug. 
 
 
 
 
 
 
 
 
Figure 3. Relationship between Dissolution Test and Absorption 
 
Dissolution provides very useful information on the performance capabilities of solid oral 
dosage forms that may be used to assist in the selection of suitable formulations. Also, it 
serves as a quality control test in support of routine manufacture to establish lot-to-lot 
Dissolution	   Absorption	  
The	  dissolution	  test	  can	  predict,	  by	  simulation,	  
what	  happens	  to	  the	  active	  ingredient	  
contained	  in	  a	  pharmaceutical	  dosage	  form,	  
when	  administered	  into	  the	  body	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performance consistencies. In fact, this test method is considered so useful that it is a 
standard method published by the United States Pharmacopeia (USP), the European 
Pharmacopoeia (EP), and the Japanese Pharmacopoeia (JP) [51].  
Dissolution testing is of great relevance, especially when [52]:  
• The drug has low aqueous solubility;  
• There is evidence that particle size may affect bioavailability;  
• The physical forms of drug (polymorphs, solvates or complexes) have 
different solubility and dissolution characteristics; 
• Specific excipients alter dissolution or absorption; 
• There is evidence that tablet or capsule coating may interfere with 
disintegration or dissolution.   
 
The main applications for testing the dissolution are [51]:   
• To study the release kinetics; 
• To develop and optimize a formulation; 
• To control manufacturing; 
• To compare the performance of various dosage forms or various 
formulations; 
• To support scale-up and post-approval changes for commercial immediate 
release and modified release product – the dissolution rate and equivalence data 
required is dependent on the magnitude of the changes;  
• For development of immediate release of the generic products – 
demonstration of equivalence of the potential generic version with the innovator 
product; 
• For new products - clinical trials are often conducted using an established 
commercial product as a comparator. Because it is important that neither the 
investigators nor clinical trial subjects are able to distinguish among the product 
under investigation, the clinical comparator, the test, and any placebo (blinding), 
the various products are made to look alike, meaning are blinded [51]. Achieving 
this with a commercial product usually involves some form of manipulation such 
as over-encapsulation and then addition of a backfill. Recognizing that such 
manipulation could affect the bioavailability of the comparator, the European 
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Medicines Agency (EMA), in its “Guideline on the Requirements to the 
Chemical and Pharmaceutical Quality Documentation Concerning 
Investigational Medicinal Products in Clinical Trials”, requires dissolution 
testing to be conducted to demonstrate that manipulations of comparator 
products have not compromised their performance [53]. 
 
 
 
2.2.2.1.	  Types	  of	  Dissolution	  Apparatus	  
 
Any dissolution test method consists in immersing the dosage unit in a suitable medium, 
which is kept in motion at a constant speed and requires the determination of the rate at 
which the drug substance is extracted from the dosage unit and dissolves in the medium 
[51, 52]. Results of this type of determination are dependent on system hydrodynamics, 
which, in turn, depend on apparatus details. The various compendia provide strict details of 
all dissolution apparatus dimensions. Fortunately, the chapters on dissolution published in 
USP, EP, and JP are harmonized [51], and single dosage units are tested in a number of 
vessels or cells (usually six). 
For orally administered immediate and delayed release dosage forms, including tablets, 
capsules and suspensions, USP Apparatus 1 (basket) or 2 (paddle) is recommended (figures 
4 and 5) [52], but generally apparatus 2 (rotating paddle) is the first choice for immediate 
release, due to ease of use, reproducibility, hydrodynamics, and general acceptance [51]. 
For extended release dosage forms, designed to deliver the drug to site absorption at a 
controlled rate over an extended period of time, USP Apparatus 3 (flow-through cell) 
(figure 6) should also be considered during method development because it allows changes 
in the medium pH during dissolution testing [51]. It should be noted, however, that USP 
Apparatus 3 is not currently recognized by the JP and should, therefore, not be considered 
for products intended for the Japanese market [51].   
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Figure 4. The rotating basket method for dissolution test (apparatus 1). Adapted from Florence and 
Attwood (2011) [52] 
	  
	  
 
 
 
 
 
 
Figure 5. The rotating paddle method for dissolution test (apparatus 2). Adapted from Florence and 
Attwood (2011) [52] 
 
 
 
 
	  
	  
	  
	  
	  
Figure 6. A recommended standard design for a flow-through cell. (The cell is 
cylindrical in shape and constructed of glass or other suitable material.  The arrows 
represent the fluid from bottom to top). Adapted from Florence and Attwood (2011) 
[52]  
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Table 4 summarizes some apparatus suggested for drug release testing of various oral 
dosage forms:  
 
Table 4. Suggested Apparatus for Drug Release Testing for most common Oral Dosage 
Forms. Adapted from Brown et al. (2011) [50] 
Oral Dosage Form Released Method 
Oral solid dosage form (conventional) Basket apparatus, paddle apparatus or flow-
through cell 
Oral suspensions Paddle apparatus 
Oral disintegrating tablets Paddle apparatus 
Chewable tablets Basket apparatus or paddle apparatus 
Powders and granules Flow-through cell 
Liquid-filled capsules Paddle apparatus 
	  
	  
	  
	  2.2.3.	  Impurities,	  Degradation	  Products	  and	  Residual	  Solvents	  
 
Impurities, degradation products and residual solvents, deriving from the manufacturing 
process or originated during storage, as well as, starting materials relevant to the drug 
substance used for the clinical trial, should be stated [53]. 
During the development of a new drug, a comprehensive set of stability tests is required, so 
the manufacturer should gather a thorough understanding of the characteristics of the 
product and how they are influenced by environmental conditions. Additionally, through 
the results from this initial assessment of stability, the manufacturer offers an open expiry 
date (open shelf-life) and defines the initial storage conditions for the product. In the 
development phase, the following studies are performed [54, 55]:  
• Forced degradation test with the following objectives: 
o To identify degradation products of the API and excipients, and to 
identify degradation conditions, with the aim to provide information 
on the development and validation of the manufacturing process and 
storage conditions of the product;  
o Identify environmental factors that could potentially influence the 
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stability of the drug, and to define which packaging materials are 
most suitable to protect the product. 
• Photostability test: conducted in at least one batch of pharmaceutical 
product, according to the requirements of the "Guideline ICH Q1B”, with 
the aim to demonstrate that the light does not cause changes in the product 
[56]. 
• Stability in use: this study should be undertaken whenever evaluating the 
stability of a multidose container, simulating normal use, and aims to 
determine the shelf-life after opening. 
 
Forced degradation studies are described in various international guidelines. The 
International Committee for Harmonization (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use has published a set of guidelines, which 
have been discussed, agreed and adopted by the American, European and Japanese 
regulatory authorities. In the majority of cases, the ICH guidelines only apply to the 
marketing applications for new products, i.e., they do not apply during clinical 
development. However, since the conditions used for forced degradation are only defined 
in general terms, it is possible to apply them for developing stability, indicating methods 
during clinical development. The same forced degradation conditions can then be applied 
to the drug substance during development and commercialization [57]. The ICH guidelines 
that are applicable to forced degradation studies are: 
• ICH Q1A – Stability Testing of New Drug Substances and Products [55]; 
• ICH Q1B – Photostability Testing of New Drug Substances and Products 
[56]; 
• ICH Q2B – Validation of Analytical Procedures: Methodology [58].  
 
In ICH Q1A, section 2.1.2 (Stress Testing), there are recommended conditions for 
performing forced degradation studies on drug substances and drug products. The 
recommendations are to examine the effects of temperature (above that for accelerated 
testing, i.e., >50°C), humidity (≥75% relative humidity), oxidation and photolysis. Testing 
in solution should also be performed across a wide pH range, either as a solution or 
suspension. These samples are then used to develop a stability-indicating method [55].  
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However, ICH guidelines do not give any guidance as to how much degradation is required 
in forced degradation studies. If too little stress is applied, some degradation pathways may 
not be observed, which would not challenge the method’s ability to detect and monitor 
degradation products during stability testing. If too much stress is applied, then unrealistic 
degradation products may be observed and the result of analytical method may be 
unsuitable for detecting degradation products formed during stability testing. Thus, the 
conditions should be chosen carefully, so that the amount of degradation of the drug 
substance produced during forced degradation is neither too excessive nor too little [57]. 
Simon [57] suggests that HPLC with mass spectrometry detection can provide valuable 
information on the structural changes occurring as a result of degradation, which can help 
in the interpretation of the degradation pathways. 
In analytical terms many drug substances have poor aqueous solubility and require addition 
of an organic co-solvent to maintain solubility [59]. Solution samples are easier to handle 
and lend themselves to increased accuracy in analytical testing. However, ICH Q1A does 
not state that solutions are required for forced degradation studies, but, in turn, suspensions 
will tend to undergo a slower rate of degradation than a solution, and typically require 
whole vial analysis to reduce errors associated with sub-sampling a suspension [57]. The 
use of co-solvents prevents all of these issues, but, however, the use of organic co-solvents 
can lead to the following [57]: 
• Increased or decreased rate of degradation; 
• Reaction products between drug substance and the organic co-solvent; 
• Peaks in the chromatogram arising from the organic co-solvent.  
 
Forced degradation of drug substances has the potential to form many more degradation 
products than those observed to form during stability testing. However, this minimizes the 
potential for not detecting the actual degradation products formed during stability testing. 
Thus, if appropriate forced degradation studies have been performed, the method can be 
considered to be stability indicating. The results from the forced degradation studies can be 
used to investigate the mechanism of degradation for a drug substance on storage. In such 
cases, the absence of observed degradation products demonstrates that the drug substance 
is stable to degradation under the storage conditions [57]. This understanding can be used 
to define the appropriate packaging, minimizing the degradation of the drug substance [57]. 
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2.2.4.	  Types	  of	  Conventional	  Formulations	  
 
Dose is a major factor controlling the type of formulation and processing [14].  
In this topic, the main types of conventional formulations will be briefly discussed, and, in 
the following topic, a major focus will be given to some new drug delivery systems.  
 
 
2.2.4.1.	  Liquid	  Formulations	  	  
 
Liquid formulations account about 30% of products in the United Kingdom market (and 
probably in other developed countries) and, because they are easy to swallow, are favoured 
for paediatrics and geriatric use [14]. An aqueous solution is the simplest formulation to 
produce, but more complex, such as suspensions or emulsions systems, will be required if 
the drug is poorly soluble. Another advantage is that liquid formulations have myriad 
possibilities of innovative drug delivery systems. One of the most desirable features of 
liquid formulations, particularly the solution forms, is the relatively lower importance of 
bioavailability considerations, as the drug molecules are already in the dispersed phase, 
removing many rate-limiting steps in the absorption of drugs [60].  
Liquid formulations are probably the most versatile systems, since they can be used for 
various routes of administration. However, liquids are difficult to transport and container 
breakage, if glass is used, can result in catastrophic loss, and, consequently, increase costs. 
Another disadvantage, is the fact that the non-sterile aqueous liquids are liable to microbial 
growth and, therefore, require the addition of antimicrobial preservatives [14]. 
A special requirement for parenteral or injectable formulations is that they must be sterile, 
apyrogenic and free from visible particulate contamination [61]. Generally, sterilization is 
conducted using a thermal sterilization method, such as autoclaving at 121ºC for 15 
minutes for aqueous liquids [61]. This is a severe challenge to the drug’s chemical stability, 
and studies must be conducted to ensure that degradation does not occur, specially for 
thermolabile compounds, which requires specialised sterilization methods [14].    
Since suspensions contain a solid drug as a disperse phase normally in an aqueous-based 
liquid, they are physically unstable, because the solid deposits. So, the formulation must be 
design to limit this phenomenon. Suspension stability is also determined by the drug’s 
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particle size, and limits will be required because small variations can induce physical 
instability if the formulation is not robust. In addition to antimicrobial preservatives to 
prevent microbial growth, flavours and sweeteners may be required to achieve the desired 
organoleptic properties [14]. 
 
 
2.2.4.2.	  Solid	  Formulations	  
 
Solid formulations, such as tablets and capsules, are perhaps the most common 
formulations marketed in the world, mainly because they have great advantages in 
providing the dose in a discrete unit form that is stable, easily produced, transported and, 
above all, easy to administered [14, 62, 63]. The tablet is favoured because it is marginally 
cheaper to produce and slightly more stable under in-use conditions [14]. The simplest 
solid dosage form is the drug powder itself, a presentation mode that is still used for some 
antacid preparation and pediatric use. 
There are three main methods of tablet manufacture, with choice depending on the dose 
and the drug’s physical properties such as compressibility and flow (see figure 7). A tablet 
with a large API dose (>100 mg) and a good flow and compressibility properties may be 
directly compressed into a tablet after mixing with suitable excipients [14], that are 
available to allow production of tablets at high speeds without prior granulation steps. 
These directly compressible excipients have desirable properties of flow and 
compressibility, and generally are substances such as lactose, sucrose, dextrose, or 
cellulose. Direct compression avoids several problems associated with wet and dry 
granulations. However, the intrinsic physical properties of the excipient are highly critical, 
and minor variations can alter flow and compression characteristics making them 
unsuitable for direct compression [63]. 
When physical properties are not ideal, some form of pre-treatment, such as granulation, is 
necessary [64]. The purpose of wet and dry granulation is to improve flow and density of 
the mixture and to enhance its compressibility [63]. In wet granulation, the drug is mixed 
with a diluent and then a solution of a polymeric binder is added during continuous mixing 
to form a wet powder mass. The mass may be passed through a sieve to produce reduced 
agglomerates. To achieve a homogeneous size, the powder is dried in hot air, and the 
	  	  
	   Development	  of	  Investigational	  Medicinal	  Products	   	  	   	  
45	  Preparation	  and	  Handling	  of	  Investigational	  Medicinal	  Products	  
resulting granules are blended with other excipients such as disintegrant, diluent and 
lubrificant. The final mixture should flow easily in order to be compressed into a tablet 
[14]. Dry granulation involves the compaction of powders at high pressures. These 
compacts are then milled and screened to form a granulation of the desired particle size. 
The advantage of dry granulation is the elimination of heat and moisture in the processing 
[63]. 
 
Figure 7. The tablet production fluxogram. (Process stages are shown in boxes). Adapted from 
Halbert (2009) [14].	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Despite representing one of the oldest pharmaceutical techniques, coating of dosage forms 
is still frequently used in pharmaceutical manufacturing. The aims of coating range from 
simply masking the taste or odor of drugs to allow control release formulations [65]. The 
traditional tablet coating is a sugar coat applied in stages as described in tablet. First, the 
tablet surface is sealed to prevent the ingress of water, and then a subcoat of an aqueous 
polymeric or sucrose solution is added to smooth the surface of the tablet. This process can 
be repeated until the desired size and shape is achieved. Finally, a coloured sugar coat is 
applied and wax polish, and the company logo may be printed on the tablets, which can 
present an expensive and laborious process. Therefore, it has largely been replaced by film 
coating, which utilizes a coat of a polymer dissolved in a suitable solvent [14]. This process 
generally does not affect the tablet performance, but could increase the manufacture 
process, and could also difficult blinding process when comparative clinical trial trials are 
performed [14].  
 
	  
2.2.4.3.	  Semi-­‐solid	  Formulations	  
	  
Semi-solid formulations are normally employed for the topical applications of drugs and 
mucous membranes in order to provide a local action. Drug can be either dissolved or 
suspended in the formulation. The semi-solid formulations most commonly used are 
emulsions, ointments and pastes.  
Emulsions are a two-phase system consisting of water and oil, that can be classified in two 
types: the oil-in-water emulsion (which has oil droplets dispersed in a continuous aqueous 
phase) and the water-in-oil emulsion (which as water droplets in a continuous oil phase) 
[66]. Oil is often chosen for its ability to solubilise the drug and its compatibility with the 
route of administration [14]. However, an oil-in-water emulsion is thermodynamically 
unstable and will tend to separate into two distinct liquid phases, being necessary the use of 
emulsifying agents to reduce interfacial tension between the oil and the water, in order to 
avoid coalescence [66]. Emulsions are also particularly sensitive to adverse storage 
conditions, such as change in temperature, and, therefore, may require specialised storage. 
Furthermore, as with all aqueous-based preparations, it will be required an antimicrobial 
preservative, as well as an antioxidant to prevent rancidification of their oil [14, 66].   
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For semi-solid products, any change in the preservative may affect the quality of the 
product. If any quantitative or qualitative changes are made in the formulation, additional 
testing should be performed. No in vitro release documentation or in vivo bioequivalence 
documentation is needed for preservative changes [67]. 
	  
	  
2.4.5.	  New	  Drug	  Delivery	  Systems	  for	  Drug	  Administration	  
	  
New insights in molecular biology, material sciences and biomedical sciences have 
produced a portfolio of new systems, materials and approaches with the potential to treat 
disease. The associated research has crossed physical, technological, chemical, biological, 
mathematical and biomedical sciences in the search for delivery systems that behave 
selectively against complex targets at the true target site, delivering optimal concentrations 
of drug at the right, and over an optimal period of time [68].  
Figure 8 schematically illustrates the long march of controlled drug delivery systems from 
the macroscopic size range nano-domain.  
 
 
 
 
 
 
 
 
 
 
	  
	  
Figure 8. A schematic representation of the progress from macro and micro delivery systems to 
the nano-domain over the period from the 19th century to today. (The dates given represent 
early discovery and significant events after discovery when there are several dates). Adapted 
from Crommelin & Florence (2013) [68].  
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Various new drug delivery systems have been developed to answer the question: How to 
get the drug to the right place in the body and how to control the release of the drug to 
prevent overdoses? 
In the next subtopics some of the most recent drug delivery systems will be discussed. 
 
	  
2.4.5.1.	  Osmotic	  Systems	  
	   	  
Much research has focused on developing drug candidates for oral administration capable 
of yielding an in vivo plasma concentration effective and reproducible, since oral 
administration is considered the most convenient. However, as most drugs have a poorly 
oral absorption or require a high frequency of administration, the modified release 
formulations are an effective method for optimizing the bioavailability and blood 
concentration profile over time (see the advantages and disadvantages use of modified 
release forms in table 5) [62]. According to the Portuguese Pharmacopoeia VIII there are 
different release profiles of drugs, such as pharmaceutical dosage form of conventional 
release, pharmaceutical dosage form of modified release, pharmaceutical dosage form of 
sustained release, pharmaceutical dosage form of delayed release and pharmaceutical 
dosage form of sequential release [69].  
The osmotic systems are currently one of the main types of modified release systems, 
which use the principle of osmotic pressure to promote the drug release, that consists in the 
presence of an osmotically active core containing the drug, covered by a rigid membrane, 
semi-permeable (permeable to the water but not to the drug), usually with a well-defined 
size hole, allowing release of the drug. In an aqueous medium, the water penetrates through 
the semipermeable membrane into the core of the system, at a rate dependent on the 
composition and thickness of the membrane, increasing the internal pressure. The fact that 
the membrane is semipermeable, meaning that the water enters the membrane at a constant 
speed, and the drug outs through the orifice also at a constant release rate during a 
prolonged period of time, ensuring a constant release of the drug [62, 70, 71].  
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Table 5. Advantages and Disadvantages of Modified Release Formulations  
Modified Release Formulations 
Advantages [62, 72] Disadvantages [62] 
Simplification of the dosage scheme Possibility of rupture of the system and 
consequent excessive release of drug 
Decrease the possibility of errors or forgetfulness Expensive 
Minor fluctuations in plasma concentrations  
Reduced gastrointestinal irritation  
Decrease of adverse reactions or toxic effects  
Absorption more effective  
Release of the drug at a determined time  
	  
	  
	  
2.4.5.2.	  Matrix	  Systems	  
	  
Nowadays, the matrix systems are perhaps the most used system [73], due to intrinsic 
advantages such as versatility, efficiency, low cost, production equipment and techniques 
[74]. In those systems, the drug is incorporated in a structure formed by chains of one or 
more chemical substances that act as release modulating agents, either in the form of 
solution or dispersion, in order to regulate the speed and location of drug release [73, 74], 
providing a duration of therapeutic activity sustained over time and/or specific delivery of 
drug at a particular tissue or cell population [74]. The inert matrices are comprised of 
insoluble materials that cause solid porous structures in which the drug is dispersed by 
maintaining the apparent surface over the release process [74].  
Drug release is quite complex, since it must be considered erosion of the matrix during the 
process. The main factor that regulate drug release are the solubility and diffusivity through 
the polymer [73]. 
Most matrix systems resort to careful selection of several types of excipients in order to 
modulate the transfer of drugs. Thus, the polymers are versatile agents to perform these 
functions [75]. 
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The matrix systems can be classified as mineral matrix, hydrophilic matrix, inert matrix, 
lipidic matrix and biodegradable non-lipid matrices [74], and may appear as tablets, but 
most commonly in microcapsules. The micro and nanoparticles are often prepared with 
inert matrices [73]. 
 
 
	  
 
 
 
 
Figure 9. Release of Drugs in Matrix Systems: a) dissolving liquid penetration into the pores of 
the matrix system, b) canaliculi by slow diffusion of dissolved drug to the exterior. Adapted 
from Lopes et al (2011) [74]	  
	  
	  
	  
2.4.5.3.	  Mucoadhesive	  Systems	  
 
The oral bioavailability of many drugs can be limited by the residence time of 
pharmaceutical dosage forms through the gastrointestinal tract [76, 77]. Once administered, 
dosage forms must undergo disintegration, dissolution of the drug employed and 
subsequent absorption through the mucosa. Since each drug has a region where absorption 
is preferred, the residence time of the dosage form/drug in this region is critical [78]. 
The mucoadhesion has been proposed as a strategy to increase the residence time of 
pharmaceutical dosage forms at a specific area and to reduce its variability [78], as well as 
to maximize systemic absorption of drugs and the performance of topically acting agents 
[79]. Thus, the therapeutic effect of the drug can be increased. 
The term mucoadhesion refers to the interaction between natural or synthetic 
macromolecules and mucus layer that lining the mucosa of the gastrointestinal tract, and 
the term bioadhesion is used when the interaction occurs at the epithelial surface. The 
Dissolution	  liquid	  
drug	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profile of a mucoadhesive formulation intended for oral administration depends on the 
strength of interaction of the components of this formulation with the mucus [76]. 
Most research has focused on mucoadhesion in the stomach and small intestine, with 
promising results observed from in vitro studies. However, the data obtained in human 
studies revealed lack of success of mucoadhesion, mainly because of the complex nature of 
the human gastrointestinal tract. In addition, most in vitro models provide little 
resemblance to the situation in vivo in several aspects such as motility, pH, thick mucus 
and sputum volume, presence of food and enzymes. Once the motility of the colon is 
lower, mucoadhesion can be most successful in this part of the gastrointestinal tract. [78]. 
Nevertheless, further studies in animals and humans, as well as pharmacokinetics studies, 
are needed to determine absorption of the drugs based in mucoadhesive systems.  
Some authors have classified such systems as gastroretentive systems.  
 
 
2.4.5.4.	  Gastroretentive	  Systems	  
 
The bioavailability of drugs with an absorption window in the upper small intestine is 
generally limited with conventional pharmaceutical dosage forms. The residence time of 
such systems and, thus, of their drug release into the stomach and upper intestine is often 
short. To overcome this restriction and to increase the bioavailability of these drugs, 
controlled drug delivery systems with a prolonged residence time in the stomach can be 
used. Approaches to achieving prolonged residence times of the devices in the upper part 
of the gastrointestinal tract include the use of bioadhesive, size-increasing, floating and 
magnetic drug delivery systems [80, 81]. 
The most common classification of gastroretentive systems is according to the principle of 
gastroretention applied (see table 6) [82]. 
Such drug delivery systems (high-density, floating, unfolding, mucoadhesive, magnetic 
systems, etc.) are interesting and present their own advantages and drawbacks. But an 
important feature to take into account is the stomach physiology, including motility 
variables (gastric emptying, small intestinal and colonic transit rates, postprandial 
frequency of contractions), and also pathological conditions such as diabetes that can 
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profoundly affect the physiological gastric state, so that specific refinements to 
formulations may prove necessary [81]. 
 
Table 6. Classification of Gastroretentive Systems and their Characteristics 
System type Characteristics 
High-density systems 
Based both on the anatomy of the stomach and 
in the gastric contents, that have a density 
similar to the water [82]. If administering 
pharmaceutical systems with a density greater 
than 2.5 g/cm3, it is conceivable that these 
systems are in the fundus of the stomach, 
where it is easier to be expelled by the 
contraction waves [83]. 
Floating systems 
These have a bulk density lower than the 
gastric content. They remain buoyant in the 
stomach for a prolonged period of time, with 
the potential for continuous release of drug 
[81]. These systems generally consist of 
hydrophilic polymers that swell upon contact 
with aqueous solutions. The combination of 
processes of swelling and erosion of the gelled 
layer that is formed, allow control of drug 
release and also the fluctuation of the 
pharmaceutical system [82]. 
Expandable systems 
These unfolding systems are made of 
biodegradable polymers. The concept is to 
make a carrier, such as a capsule, incorporating 
a compressed system, which extends in the 
stomach. In spite of their interesting 
characteristics, expandable systems have 
drawbacks. Storage of such easily 
hydrolysable, biodegradable polymers is 
problematical [81]. 
Mucoadhesive or bioadhesive systems 
In mucoadhesive systems occurs interaction 
between natural or synthetic macromolecules 
and mucus layer that lining the mucosa of the 
gastrointestinal tract, increasing the residence 
time.  
Magnetic systems 
This system is based on a simple idea: the 
dosage form contains a small internal magnet, 
and a magnet placed on the abdomen over the 
position of the stomach [81]. 
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2.4.5.5.	  Transdermal	  Systems	  
 
The delivery of drugs through the skin provides a convenient route of administration that is 
often preferable to injection because it is noninvasive and can typically be self-
administered, resulting in a significant reduction of medical complications and an 
improvement in patient compliance. Unfortunately, a significant obstacle to transdermal 
drug delivery is the resilient barrier that the epidermal layers of the skin, primarily the 
stratum corneum, present for the diffusion of exogenous chemical agents [84]. 
Transdermal delivery use the skin as the application site, introduces the drug for transport 
into the circulatory system, keeping a constant plasma concentration [85, 86]. The delivery 
of drugs through the skin provides a convenient route of administration that bypasses the 
gastro-intestinal tract, first-pass metabolism, and many of the complications associated 
with injectable drugs [85]. 
Furthermore, these drug delivery systems have another advantages, such as [86]:  
• Prevents degradation of the drug in gastrointestinal tract due to 
enzymatic conditions; 
• Promotes the absorption of drugs at therapeutic doses and maintain 
adequate plasma concentrations constants; 
• Reduces the frequency of administration; 
• Avoids the first-pass metabolism; 
• Allows immediate discontinuation of the administration; 
• Enables a constant drug plasma levels; 
• Promotes adherence to therapy; 
• It is a noninvasive drug delivery system.  
 
However, because the skin is extremely effective at protecting the body from external 
pathogens and toxins, transdermal delivery systems must be designed to circumvent its 
barrier properties [85]. 
The drugs candidates for transdermal route of administration must have physicochemical 
characteristics suitable for penetrating the skin barrier, i.e. high pharmacological potency, 
non-irritating, low polarity, non-ionized form, low-mass molecules and appropriate 
partition coefficient [86]. 
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2.4.5.6.	  Hydrogels	  
 
The properties of hydrogels, in particular their high biocompatibility and water sorption 
uptake, make hydrogels very attractive in drug delivery and biomedical devices [87]. 
However, these favorable features of hydrogels are compromised by certain structural 
limitations, such as those associated with their low mechanical strength in the swollen state 
[88].   
Hydrogels are a hydrophobic polymeric network of three-dimensional structures consisting 
of single chain or multiple chains of polymers (monomers) being cross-linked [87], making 
them insoluble in water, due to ionic interaction and hydrogen bonding. The network 
structure of hydrogels can be macroporous (hydrogels that release the drug entrapped 
inside the pores through a mechanism dependent on drug diffusion coefficient), 
microporous (the drug release are made by molecular diffusion and convection) or 
nonporous (the release of drug is only by diffusion mechanism) [89]. 
These hydrogels, being biocompatible and biodegradable in nature, have been used in the 
development of nano-biotechnology products and have important applications in the field 
of controlled drug delivery, gaining attention as intelligent drug carriers [89]. 
 
 
2.4.5.7.	  Micro	  and	  Nanoparticles	  
 
The reason behind the failure of conventional delivery systems in reaching the brain is the 
blood brain barrier composed of tight tissues making it impervious to outside agents [90]. 
Nanotechnology has the potential to address and resolve this challenge and make brain a 
reachable target for drug delivery systems, by combining unique elements of size, surface 
activity and charge of nanostructures [91]. Micro and nanoparticles have brought new ways 
in diagnostics and therapeutics [90]. Nanodelivery of drugs is predicted to reduce collateral 
damage, extend the drug's availability and effectiveness at the site, and reduce toxicity and 
cost with a high pay-off load [91]. 
Micro and nanoparticles are defined as solid systems based on polymers (synthetic, semi-
synthetic or natural), or other materials, of biodegradable nature or not, with dimensions on 
the order of micrometers and nanometers, respectively, and serving as a vehicle for drugs. 
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As regards the structure, the term micro and nanoparticle comprises two more specific 
types: the micro and nanospheres, and micro and nanocapsules [92]. 
As noted by several authors, the nanoparticulate systems are promising as active vectors 
due to their ability to release drugs [93], and their subcellular size, allowing relatively 
higher intracellular uptake in comparison with other systems. In addition, they can improve 
the stability of drugs, and may be biocompatible with the tissue and cells [94].  
The nanoencapsulated systems include high drug encapsulation efficiency due to the 
optimized drug solubility in the core, low polymer content compared with other 
nanoparticulate systems, such as nanospheres, and protection against degradation factors 
such as pH and light, and the reduction of tissue irritation due to the polymeric shell [94, 
95]. Nanocapsules can be compared to vesicular systems, where drug is confined to a 
cavity consisting of a liquid core surrounded by a polymeric membrane [92, 94].  
The cavity can contain the drug in liquid or solid form, or as a molecular dispersion [95, 
96]. The reservoir may be lipophilic or hydrophobic according to the preparation method 
and raw materials used. Furthermore, taking into account operational constraints 
preparation methods, nanocapsules can also carry the active substance on its surface or 
impregnated in the polymeric membrane [92, 94].  
 
 
 
2.4.5.8.	  Vesicular	  Systems	  
 
During the past decade, formulation of vesicles, as a tool to improve drug delivery, has 
created a lot of interest amongst the scientist working in the area of drug delivery systems. 
Vesicular systems, such as liposomes and niosomes, provide an alternative to improve the 
drug delivery [97]. These systems, especially liposomes, have generated a great interest, 
since they can be used as sensitive containers that respond to external stimuli to delivery 
the drug, such as pressure, pH, temperature, or concentration changes in the medium, 
producing modifications in their structure. The control of the nanostructure-particle size 
and size distribution, membrane morphology, and supramolecular organization of these 
self-assembled systems is of great importance for their application in drug delivery [98]. 
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2.4.5.8.1.	  Liposomes	  
 
Liposomes are a well-known and well-used vesicular delivery system, formed by a lipid 
bilayer surrounding an aqueous solution. They can deliver both hydrophilic and lipophilic 
actives to their target across the stratum corneum [99, 100]. The diameter and number of 
layers depend primarily on the manufacturing process, with the multilamellar, large 
unilamellar and small unilamellar vesicles (table 7) being the most commonly used [101]. 
 
 
Table 7. Classification of Liposomes according to their Diameter. Adapted from Matos & 
Moutinho (2011) [101] 
Type of liposomes Diameter (nm) 
Multilamellar Vesicles (MLV) 
(Also known as conventional liposomes or first 
generation liposomes) 
500-5000 
Large Unilamellar Vesicles (LUV) 100-500 
Small Unilamellar Vesicles (SUV) 20-100 
 
 
Many reviews and book chapters have focused on the application of liposomes for drug 
delivery, gene therapy, and immunization. 
It is important to highlight the many advantages of liposomes, such as [101-104]: 
• To protect the drug from potential instabilities; 
• To promote a constant concentration; 
• To promote gradual and controlled release of the drug; 
• To decrease toxicity; 
• To target specific cells or organs; 
• To incorporate both hydrophilic substances or lipophilic substances; 
• To decrease the number of doses; 
• To reduce the total time of the treatment, which leads to an increase in 
therapy acceptance by the patient. 
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Classically, liposomes can be prepared from mixtures of amphiphilic lipid (phospholipid 
and cholesterol) extracted and purified natural or from synthetic lipids [101, 102, 105].  
The cholesterol, as well as triglycerides or propylene glycol esters, make the membrane of 
liposomes more waterproof, allowing sustained release of the drug. The control over the 
rate of drug release by the vesicle can also be achieved by manipulating the size, surface 
area and membrane fluidity [101]. 
Liposomes are predominantly removed from circulation by phagocyte cells of the 
reticuloendothelial system, which may lead to accumulation of a large extent in organs like 
liver and spleen. This biodistribution pattern can be used for passive targeting of 
diagnostics to these organs, but information on biodistribution is, therefore, important for 
drug targeting by liposomes [102, 105]. 
Liposomes given intravenously usually interact mainly with opsonins, which bind to the 
surface of vesicles and mediate their endocytosis by the mononuclear phagocyte system 
(macrophages). The rate of liposome clearance from blood circulation will, therefore, 
depend on the ability of opsonins to bind to the liposome surface [102]. 
On the other hand, there are also constraints in the commercialization of liposomal 
preparation. First, the lipids needed for their preparation are scarce, should be of high 
purity and, hence, expensive. Secondly, liposomal preparations are inherently unstable 
[103] and require special storage conditions even when the products are freeze-dried. As a 
result of this stability problem, the dosage forms are limited to injection (freeze-dried) 
powders for reconstitution immediately before use [102]. 
 
 
2.4.5.8.2.	  Niosomes	  
 
Niosomes are multilamellar vesicular structure of non-ionic surfactants (instead of 
phospholipids), similar to liposomes [97, 106], widely studied as an alternative tool to 
liposomes [97]. 
Niosomes contain mainly two types of components i.e., non-ionic surfactant and the 
additives. The non-ionic surfactants form the vesicular layer. Additives used in niosome 
preparation are usually cholesterol [106] that improves the rigidity of the bilayer, affecting 
it fluidity and permeability. This carrier system protects the drug molecules from the 
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premature degradation and inactivation due to unwanted immunological and 
pharmacological effects.  
As a drug delivery system, niosomes are more stable and cheap compared to other 
vesicular systems. In recent years, niosomes have been extensively studied to delivery of 
various therapeutically active moieties, such as gene delivery, anti-cancer agents, 
hormones, antigens, anti-inflammatory agents, and anti-infective agents [97, 106, 107]. 
Besides this, niosome has been used to solve the problem of insolubility, instability and 
rapid degradation of drugs [108, 109]. While selecting a suitable drug for niosomal drug 
delivery, it should be kept in mind that niosomes encapsulating hydrophobic drugs and 
macromolecules are more stable than niosomes encapsulating low molecular weight drugs. 
These factors also affect niosome stability in vivo [106]. 
The niosomes, as a drug delivery system, offer the following advantages [97, 106-109]: 
• Can be utilized in the delivery of wide variety of drugs as it has capability to 
entrap hydrophilic, lipophilic, as well as amphiphilic drugs; 
• Controlled and sustained release of drugs due to depot formation; 
• Greater bioavailability than conventional dosage forms; 
• Effectively used in targeting drugs to various organs; 
• More stable than liposomes; 
• Increase the permeation of drugs through the skin; 
• Administrated via various routes like oral, parenteral and topical etc; 
• Biodegradable, biocompatible and non-immunogenic to the body; 
• Easy handling, storage and transportation; 
• Protect the drugs from biological enzymes and acid, leading to the drug 
increase; 
• Penetration enhancers in the ocular drug delivery system cause no tissue 
irritation and damage. 
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2.4.5.9.	  Microemulsions	  and	  Nanoemulsions	  
 
The application of microwave technology to the preparation of drug products has become 
increasingly important. The micro and nanoemulsions are very promising therapeutic 
systems, presenting technological advantages that enable the optimization of 
pharmaceutical operations, such as emulsification and solubilization of drug, avoiding 
problems relating to thermodynamic instability of classic emulsions [110, 111]. 
Microemulsions are clear, stable, isotropic mixtures of oil, water and surfactant, frequently 
in combination with a cosurfactant. These systems act as drug delivery vehicles by 
incorporating a wide range of drug molecules [112]. 
Until now, microemulsions have been shown to be able to protect labile drug, control drug 
release, increase drug solubility, increase bioavailability and reduce patient variability. 
Furthermore, it is possible to formulate preparations suitable for most routes of 
administration. But fundamental work to characterize physicochemical behavior of 
microemulsions needs to be performed. [112, 113]. 
Nanoemulsions are a class of colloidal systems liquid-liquid, transparent or translucent, 
with very small uniform droplets, between 5 and 200 nm [114-116]. 
According to the preparation of such systems, the drug is dissolved in the lipophilic part of 
the nanoemulsion, i.e. oil and the water phases can be combined with a surfactant or co-
surfactant, and then added at slow rate with gradual stirring until the system is transparent. 
Finallys, ultrasonicator is used to achieve the desired size range for dispersed globules, 
allowing equilibrium [115].  
Nanoemulsions have several advantages, and many of them are common to the 
microemulsions [110, 115, 116]:   
• Increase the rate of absorption; 
• Helps solubilize lipophilic drug; 
• Provides aqueous dosage form for water insoluble drugs; 
• Increases bioavailability; 
• Various routes, such as tropical, oral and intravenous, can be  used to deliver 
the product;  
• Provides protection from hydrolysis and oxidation of drugs; 
• Same nanoemulsions can carry both lipophilic and hydrophilic drugs; 
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• Improves the efficacy of a drug, allowing the total dose to be reduced and 
thus minimizing side effects. 
 
However, there are also some disadvantages regarding nanoemulsions [115]: 
• Large concentration of surfactant and co-surfactant is necessary for stabilizing the 
nanodroplets;  
• Nanoemulsion stability is influenced by environmental parameters, such as 
temperature and pH.  
 
 
2.4.5.10.	  Solid	  Lipid	  Nanoparticles	  
	   	  
Polymeric nanoparticles, which are generally made with suitable biodegradable polymers, 
have been shown to prolong the release of the incorporated drugs [117] and have been 
developed as an alternative to liposomes [118]. Solid Lipid Nanoparticles (SLN) consist on 
a solid matrix at body temperature, with physiological lipids, coated with surfactants, and 
with sizes between 50 and 1000 nm [119]. SLN attracted increasing attention as an 
efficient and non-toxic drug carrier [120, 121]. Furthermore, they can be produced to 
incorporate lipophilic or hydrophilic drugs [122, 123]. Their colloidal dimensions and the 
controlled release behavior enable drug protection and administration by parenteral and 
non-parenteral routes, emphasising the versatility of this nanoparticulate carrier [120, 121, 
124]. 
	  
	  
2.4.5.11.	  Nanosponges	  
	  
Nanosponges are a new class of materials made of microscopic particles with few 
nanometer wide cavities, in which a large variety of substances can be encapsulated within 
its core. Both lipophilic and hydrophilic substances can be incorporated, and one of the 
main advantages is solubility improving of poorly water-soluble molecules [125-127]. 
Also, nanosponges can be used to increase the dissolution rate and stability of drugs [125, 
126]. 
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The nanosponges are solid in nature and may be used in formulations for use by various 
routes of administration. For the oral administration, they can be dispersed in excipients, 
diluents and lubricants. For the parenteral administration they can simply be carried in 
sterile water, saline or other aqueous solutions [125]. For topical administration they can be 
effectively incorporated into topical hydrogel [128].  
 
 
2.4.5.12.	  Modified	  Release	  by	  Activation	  of	  Pro-­‐drugs	  
 
A strategy to improve several parameters of pharmacologically potent compounds is the 
development of pro-drugs. A pro-drug is a chemically modified version of the drug that 
must undergo biotransformation in vivo to release the active drug [129-131]. Pro-drugs 
provide possibilities to overcome various barriers, such as [132, 133]: 
• Poor aqueous solubility; 
• Chemical instability; 
• Insufficient oral absorption; 
• Rapid pre-systemic metabolism; 
• Inadequate brain penetration; 
• Toxicity and local irritation; 
• Improve drug targeting. 
 
The drug–promoiety complex (drug and promoiety are covalently linked by a chemically 
or enzymatically labile bound) is typically pharmacologically inactive developed to cross a 
barrier, which can be any obstacle that prevents optimal (bio)pharmaceutical or 
pharmacokinetic performance [133, 134]. The ideal pro-drug yields the parent drug with 
high recovery ratios, with release of a non-toxic promoiety (figure 10) [132, 133]. 
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Figure 10. Representative Illustration of the Pro-drug Concept. Adapted from Rautio et al (2008) 
[133] 
	  
According to Rautio et al, currently 5–7% of the drugs approved can be classified as pro-
drugs, and approximately 15% of all new drugs approved in 2001 and 2002 were pro-drugs 
[133].  
	  
 
2.4.5.13.	  Modified	  Release	  by	  Inclusion	  of	  the	  Drug	  in	  CDs	  
	  
The molecular encapsulation of drugs by CDs is very advantageous from a technological 
and biological standpoint, because allows to modify the physical, chemical and 
biopharmaceutical properties of the drug, being easily to produce and less expensively than 
the encapsulation of drugs by other methods [135-137]. 
CDs are considered the most important supramolecular structures, because of their 
capability to form inclusion complexes with a variety of molecules, including inorganic, 
organic, or organometallic molecules [138]. 
The CDs have the ability to release the drug at its target site, like brain, colon or specific 
cells, when the drug is covalently bonded to the CD, preventing the dissociation of the 
drug-CD complex before reaching the specific site of action [137, 138]. 
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2.4.5.14.	  Modified	  Release	  by	  External	  Activation	  
	  
The concept of "targeting of a drug", suggested by Paul Ehrlich (physiologist and Nobel 
Prize in Medicine, 1908) in 20th century, consider a hypothetical "magic bullet", as an 
entity integrating two components: the first should be able to recognize the target and bind 
to it, while the second should provide a therapeutic action in that target [139]. The need for 
delivery of drugs with efficacy and safety has been the driver force for development of new 
systems for controlled drug release [140].  
The preparations for controlled release of drugs may [141]: 
• Maintain the concentration of drug in the desired therapeutic range by a 
single dose; 
• Target release, reducing its systemic distribution; 
• Preserving drugs that are rapidly eliminated by the body; 
• Increase efficacy and safety, improving patient comfort and adherence to 
therapy. 
 
There are three major mechanisms by which drugs may be released from a system: 
diffusion, degradation, and expansion followed by diffusion [141, 142]. Dissolution or 
degradation-controlled drug release is based on dissolution or degradation of the polymer's 
membrane that encapsulate the drug, or polymer's matrix that contain the drug [142]. 
It is also possible to design a system for drug release, which it is unable to release its 
contents before being placed in a suitable biological environment - controlled release 
systems for expansion. These systems are initially dry, and when introduced in the body 
they expand by absorbing water or body fluids [141]. Most materials used in controlled 
release systems by the expansion are based on hydrogels. Such hydrogels can show a 
response to the external or internal stimuli, such as temperature and pH. Electrically 
responsive hydrogels (normally consist of pH sensitive polyelectrolytes) have also been 
recently developed [143, 144]. It is important to note that such systems, environmentally 
sensitive or "smart" drug release, is only achieved when the polymer expands. [141, 143]. 
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2.4.6	  Biopharmaceuticals	   	  
	  
A biological product is defined as “a virus, therapeutic serum, toxin, antitoxin, vaccine, 
blood, blood component or derivative, allergenic product, or analogous product, or any 
other trivalent organic arsenic compound, applicable to the prevention, treatment or cure of 
a disease or condition of human beings” [145]. The characterization of a biotechnology 
product is more complicated and may include the determination of secondary and tertiary 
structures, degree of glycosylation, biological activity, isoform activities, impact of 
truncation of the molecule, amino acid sequence changes, pegylation, presence of 
neutralizing antibodies, and immunogenicity of the compound [40].  
The manufacture of biological medicinal products involves certain specific considerations 
arising from the nature of the products and the processes, and some particular precautions 
are needed. Unlike conventional medicinal products (high degree of consistency), the 
production of biological medicinal products displays an inherent variability since it 
involves biological processes and materials, such as cultivation of cells or extraction of 
material from living organisms [145, 146]. 
The manufacturing processes for biologics, typically derive from living systems, which can 
be complex [147]. Biological products can be isolated from naturally derived sources or 
manufactured using bacteria, yeast, fungi, insect cells, plant cells, mammalian cell cultures, 
transgenics, and other system. Bioprocessing of proteins involves the integration and scale-
up of upstream and downstream processing, process monitoring, optimization and control. 
The manufacture of proteins requires strict control of the starting raw materials, genetic 
engineering, expression systems, optimization of growth conditions, batch culture design, 
purification, protein analyses, formulation, analytical testing, stability, aseptic filling, 
packaging and the validation of the processes [148]. Careful monitoring of critical process 
variables provides product quality assurance and the understanding of how these process 
variables affects the final product [146, 148]. 
As with small molecules, the biological manufacturing process is intimately associated 
with the quality of the biological product. In general, biological manufacture can be 
divided into two main processes: upstream and downstream processing (figure 11) [147, 
149, 150]. Upstream activities produce the protein of interest, usually by cell culture or 
fermentation [147-149]. Upstream considerations include integrity and quality of the 
process, cell banks, expression systems, cultivation, process/product purity, impurities, and 
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contaminants [148, 151]. Downstream processing refers to the separation and purification 
of the bulk bio-product into a form suitable for its use [150, 151]. This usually includes the 
purification, sterilization, and final formulation [148]. Typically, downstream processing 
techniques include filtration, centrifugation, precipitation, numerous chromatographic 
separations, and sterilization by aseptic processing, terminal filtration, or lyophilization 
[150, 152, 153].  
The complexity associated with the manufacturing of biotechnology-derived products by 
the many available biotechnology processes may result in different impurity profile, which, 
if not controlled, could lead to therapeutic nonequivalence or immunogenic responses 
between similar biologics. Proving pharmaceutical equivalence between multisource 
biologics may be possible; however, the analytical procedures may be limited in their 
ability to detect heterogeneity, glycosylation, and conformational changes associated with 
complex biologics [148]. 
 
 
 
 
 
 
	  
	  
 
 
	  
	  
	  
Figure 11. Biopharmaceutical Manufacturing Process. Adapted from Sekhon (2010) [147] 
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CHAPTER	  3	  
Production	  of	  Investigational	  Medicinal	  Products	  
 
	  
Investigational medicinal products should be produced in accordance with the principles 
and the detailed guidelines of GMP for Medicinal Products (The Rules Governing 
Medicinal Products in The European Community, Volume IV), although other guidelines 
published by the European Commission should be taken into account according the stage 
of development of the product [11]. 
The production of investigational medicinal products involves added complexity in 
comparison to marketed products, due of the lack of fixed routines, variety of clinical trial 
designs, consequent packaging designs, and the need, often, for randomization and 
blinding, as well as increased risk of product cross-contamination and mix up [11, 154]. 
The major pharmaceutical challenge is to develop the appropriate manufacturing and 
packaging procedures that ensure the stability and quality of the trial supplies. In addition, 
blinding may be required by the clinical trial protocol. The simplest trial would be active 
product against matching placebo in a single dose level. However, multiple dose levels or 
comparisons with competitors’ products, increase the complexity of supplies and 
pharmaceutical demand [14].  
  
	  
3.1.	  Scale-­‐up	  and	  Manufacture	  
 
The development and optimization of a formulation is an experimental phase (conducted in 
small batches of the material), but the overall aim of pharmaceutical development is to 
transform the formulation into a product that can be manufactured on a large scale. The 
complexity of scale-up is related to the proposed production batch size of the final product 
[14].  
For every manufacturing operation or supply there should be adequate written instructions 
and written records. Records are particularly important for the preparation of the final 
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version of the documents to be used in routine manufacture once the marketing 
authorization is granted [11]. 
The first opportunity for a formulation scientist to scale-up the formulation is when the 
clinical supply requirements justify the need for larger batches [155].  
Production processes for IMP are not expected to be validated duo to the extent necessary 
for routine production, but premises and equipment are expected to be qualified. For sterile 
products, the validation of sterilising processes should be of the same standard as for 
products authorised for marketing. Similarly, when products of biological origin are used, 
safety of products should be demonstrated by following the scientific principles and 
techniques defined in the guidance for this area. Validation of aseptic processes presents 
special problems when the batch size is small. If practicable, a larger number of units 
should be filled to provide greater confidence in the results obtained. Enhanced training 
should be given to operator, because filling and sealing is a manual or semi-automated 
operation that presents great challenges to sterility [11]. 
Regulatory authorities will inspect the production premises and processes to ensure that 
everything complies with the license application and the GMP, that must be maintained 
throughout the production cycle, including, suppliers and also distribution chain. In fact, 
GMP should only end when the product is handed to the patient [14].  
The clinical formulation should have at least a year shelf-life at the specified storage 
condition. Attention should be taken to the time spent for clinical supplies manufacture, 
package and label the clinical material, and ship the supplies to the clinical site. The 
number of dosage strengths and placebos also will affect the manufacturing lead times 
[155].  
Formulation development personnel, pilot plant staff, quality assurance, quality control, 
validation, and other support functions need to closely coordinate their activities and 
responsibilities [155].  
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3.1.1.	  Facilities	  for	  Production	  of	  Clinical	  Supplies	  
 
It is ideal to have a pilot plant that should be design to support product development 
activities and clinical supplies manufacture according to the GMP [156].  
Clinical supplies demands increase quickly from a few hundred units to several million, 
especially for phase III and post-approval programs where larger batches sizes are common 
[157]. Companies that do not have a pilot plant capable of handling these larger batches 
sizes often use a contract manufacture.  
A new drug may require equipment and processes at more than one plant for its production 
[158]. Generally, an API require its own manufacturing facility, either due to safety or the 
complexity of the process [158]. API’s are typically manufactured in a chemical (or 
biological) site, whereas the filling and finishing normally are separated from the synthetic 
production, due to the higher level of cleanliness and different types of operations, 
equipment and levels of technical knowledge required by the operators [158]. Briefly, 
processing of clinical trials supplies for most therapeutic areas requires facilities designed 
to prevent cross-contamination in a controlled environment [159] .  
Facilities in which cytotoxic clinical supplies are produced must be designed and 
engineered to protect workers and the environment. Special heating, ventilation and air 
conditioning systems, as well as computer-balanced room pressure differentials and 
strategic placed airlocks, are essential to protect the workers and the product [159, 160]. 
High efficiency particulate air, so called HEPA, filtration on the facility’s exhaust air, 
neutralization of aqueous effluent, and proper disposal of organic solvent or sold wastes 
help protect the external environment [159].  
 
 
3.1.2.	  Production	  Team	  	  
	  
The facility needs to have proper support staff and functions to provide training, validation, 
maintenance, calibration, engineering, microbiological/environmental monitoring, 
warehousing, dispensing, housekeeping, quality assurance, and quality control [157]. 
All personnel whose activities are performed in areas of potential exposure to toxic 
substances must be trained in safe handling techniques and should receive appropriate 
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information, such as that provided in material safety data sheet before starting their work 
[159].  
Facility staff should also hold periodic safety meetings to review existing procedures and 
identify any areas of deficiency or need for update resulting from change of process or 
procedure. All staff should have appropriate personal protective equipment, depending on 
the type of product that will handle. They should also remove accessories such as watches, 
bracelets, rings, etc., where toxic material may be present. 
Employees who are potentially exposed to anticancer materials should participate in an 
appropriate medical surveillance program [161, 162]. 
 
 
 
3.1.3.	  Critical	  Aspects	  of	  Production	  Process 
 
3.1.3.1.	  Comparators	  
	  
According to regulatory definitions (EU Annex 13), a comparator medication are “an 
investigational or marketed product (i.e. active control), or placebo, used as a reference in a 
clinical trial” [11, 163]. In other words, comparators are positive control active drug 
supplies, and their therapeutic activity during a clinical trial essentially validates the study 
and establishes the base line for efficacy with which to compare the drug under study 
[157].   
While comparison against a placebo is generally required by regulatory authorities (despite 
some authorities considering placebo controlled trials as non-ethical), trials can also 
include an active comparator when a pharmaceutical company seeks to claim superiority or 
non-inferiority versus the competitor drug in its marketing materials [164]. 
Pharmaceutical companies are pressured to conduct comparative effectiveness trials, and 
they should create robust strategies to select the comparator, as well as its source, in order 
to provide the drug in an uninterrupted manner to at all trial sites [164].   
Since most clinical trials should follow a blind design, the identity of the drug and/or 
comparator should be blinded to the patient and investigator [157]. Thus, comparators that 
are easier to blind or do not require extensive development time are usually chosen [157].  
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3.1.3.2.	  Blinding	  of	  Comparators:	  blinding	  operations	  
	  
Clinical dosage forms must be “blinded” with the aim to avoid bias in the clinical program.  
Especially for clinical phases II and III studies it is necessary to take into consideration 
several aspects for the appearance of the clinical trial medication, which might be contrary 
in regard to the appearance for marketed products [163]. 
Blinding is a manipulation or manufacturing technique that renders different drugs and 
placebo indistinguishable from each other. Thus, the NCE, comparator drug, and placebo 
product should have exactly the same look, feel, color, weight, shape, size, texture and 
taste [14, 157]. Also, the market image of the comparator must be “blinded” [157]. 
According to Jeatran and Clark [165], it is important to consider the drug treatments in 
terms of five senses, and every effort should be extended to mask any potential deviations, 
including those in table 8.  
 
 
Table 8. Points to Consider when Blinding Treatments. Adapted from Jeatran and Clark (1998)  
[165] 
Sight Size, shape, color, markings, packaging, labelling 
Smell Odor of the dosage form or vehicle 
Sound A tablet inside a capsule must not rattle 
Taste Mask any unique taste of study drug and comparator 
Touch Coatings, isotonicity, viscosity, route of administration 
 
 
In the ideal scenario, the positive control drug (PCD) used in a comparative, double 
blinded clinical study would be identical in appearance and dosing to the investigational 
drug. But in real life, this seldom, if ever, occurs. Marketed drugs are available in an 
almost infinite variety of size, shape, and colour. In addition, there are differences in the 
route, volume, and interval of administration, and unique packaging for many marketed 
drugs. Moreover, it is critical to consider stability and bioavailability to ensure that the 
drug is fully potent and available to have valid comparison. It is also important to ensure 
that the PCD and IMP are prepared to maximize patient compliance with dosage regimen. 
All these facts, make every new effort to prepare a blinded PCD a challenge [165].   
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If the NCE is a different dosage form than the comparator, a double-dummy approach is 
used, in which patient has to administer two products at one time, only one of them 
contains the active drug. The advantage is that both products are used without 
manipulation, but it can be very confusing for the trial participants, because increases the 
number of units per intake. In these cases, it is important to provide easily and explicit 
instructions to the patient, employing pictures and pictograms on the patient kit to increase 
compliance [14]. In both cases, neither the patient nor the clinician would know which 
active drug was being administered. Table 9 defines common types of blinding used in 
clinical studies.   
 
Table 9. Common Types of Blinding used in Clinical Studies. Adapted from Jeatran and Clark 
(1998) [165] 
Open Label No blinding is used; participants know the identity of the treatment  
Single Blind Only the patient is blinded 
Double Blind The patient and clinical investigator are blinded 
Triple Blind The patient, the clinical investigator, and the sponsor are blinded 
Double Dummy Using active and placebo form of both the study drug and the positive 
control drug or drugs to blind a study 
Third Party Blinding Use of an unblended third party (e.g. pharmacist or nurse) to dispense 
drugs to blind a study 
 
 
There are many blinding options available today (table 10), i.e., deprinting, mill & fill, 
remove markings, overcoat, similar-looking products, etc. [166], but over-encapsulation 
method still seems to be the most popular method. Perhaps over-encapsulation is not the 
least complex, but it is the most commonly chosen option for blinding clinical supplies 
[167, 168]. Indeed, the over-encapsulation nowadays is a state-of-the-art technique for 
blinding of comparators, which consists in the over-encapsulation into hard gelatine 
capsules [163].   
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Table 10. Techniques and Considerations for Blinding of Drug Products. Adapted from 
Carney et al (1995) [166] 
 
 
Type of original 
oral dosage form 
Technique Considerations 
Tablet 
Removal of markings 
Time consuming and manually intensive; 
Still must match size/shape/color of tablet; 
Process may alter release properties of a film 
coating. 
Over-encapsulation 
Time consuming and manually intensive; 
Patients may open capsule and discover original 
dosage form. 
Grinding and re-tableting 
Properties of new dosage form may be different 
from original form, affecting patient response; 
Complexity in developing new formulations.  
Grinding and encapsulating 
Properties of new dosage form may be different 
from original form, potentially affecting patient 
response; 
Assuring blend uniformity of grinded dosage 
form while encapsulating;  
Manually intensive, unless automated 
encapsulating equipment is available.  
Tablet overcoating 
Tablets are developed to match original dosage 
form; 
Preserves original dosage form; 
Pharmaceutical testing (i.e. dissolution) can help 
verify similarity to original dosage; 
Cannot be used for embossed tablets.  
Capsules 
Removal of markings 
Time consuming and manually intensive; 
Still must match size/shape/color of capsule. 
Over-encapsulating Same as above tablets. 
Grinding and re-encapsulating 
Capsule shells from original dosage form may 
be visible in manufactured product.  
Removing ingredients from 
capsule shells and encapsulating 
Manually intensive; 
Time consuming; 
Most capsules are difficult to open. 
Oral solutions 
Matching solution without 
active ingredient 
Taste and odor may be unique to active 
ingredient; 
Discoloration of active ingredient over time 
may occur and cause unblinding. 
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Over-encapsulation corresponds to basically hiding another dosage form, tablet or capsule, 
inside a capsule shell. It is important to select the appropriate components that will be 
needed to support the over-encapsulation of the tablet or capsule unit. Once the unit has 
been identified, the first thing to determine is what size capsule shell will needed to be 
utilized to properly blind each unit. Although it is not completely necessary, it is 
recommended that the unit that is being encapsulated does not protrude above the body of 
the capsule shell when inserted. The most common challenges of over-encapsulation are its 
possible effect on dissolution, disintegration, and bioequivalence in clinical trials, as well 
as the interaction between the backfill and the gelatin capsules [167, 168]. However, 
according to the GMP regulations, study sponsors must provide data demonstrating that 
over-encapsulation will not alter product quality. So, the use of backfill requires additional 
compatibility and pre-formulation studies. The dissolution profile of an over-encapsulated 
product largely depends on the properties of the API, the characteristics of the over-
encapsulated unit, and the backfill [168, 169]. According to Faust (1999), the choice of 
backfill may affect dissolution of an over-encapsulated comparator product [170]. Lab tests 
showed that the dissolution of the over-encapsulated drug has a time interval of about plus 
5-10 minutes in comparison to the original product [163]. 
 
 
 
3.1.3.3.	  Sourcing	  and	  Development	  of	  Comparators	  
	  
As mentioned above, comparative effectiveness studies for new drugs are multicenter, and 
trials can include an active comparator, despite of comparison against a placebo, is 
generally required by regulatory authorities, mainly when a pharmaceutical company seeks 
to claim superiority or non-inferiority versus the competitor drug in its marketing materials 
[164, 171]. 
The process of sourcing and supplying comparator drugs for global clinical trials represents 
a number of obstacles and potential pitfalls for the trial sponsor [171, 172]: 
• Inability to obtain the necessary pedigree and product documentation for the 
comparator; 
• Lack of supply chain security with possible introduction of counterfeit 
comparators; 
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• Delays in resupply throughout the course of the trial.  
 
Drug developers must have a comprehensive view of what is involved in the process and 
formulate a strategic approach to best support their trials [164, 171]. 
In order to minimize the risk of delayed or interrupted clinical trials and the financial 
implications that can result from it, a comparator sourcing and supply strategy should 
include a number of elements, such as [164, 171]: 
• A thorough understanding of global regulation governing sourcing; 
• Proactive demand planning that can rapidly predict changes in the quantity 
of comparator needed, duo to patient enrollment or unexpected trial 
changes. 
 
One of the simplest ways to reduce risk during the comparator sourcing process is to start 
planning early, typically during the protocol design phase [171], because the ultimate goal 
of comparator sourcing is to get the right drug, to the site, at the right time. Indeed, the 
efficient management and movement of trial supplies, including comparator drugs, is an 
important factor in the success of any trial [164]. 
According to Dutta [164] and Goodson et al [157], sourcing directly from a manufacturer 
enables access to large, single lots of the comparator with maximum shelf-life, and specific 
batch numbers when possible. Comparators with a maximum shelf-life provides time for 
characterization, demonstration of bioequivalence, relabeling and repackaging, if needed, 
while minimizing the frequency of costly resupply [164]. 
Regarding to development of comparators, it is very similar to NCE development, but is 
somewhat abbreviated on a compressed time line [157]. The development should start with 
an assessment of potential blinding techniques. So, the formulator should strive to 
minimize the potential risk of producing a blinded dosage form that does not perform 
exactly as the initial comparator product, and choose the blinding technique that requires 
least amount of manipulation, maximizes the potential to manufacture a bioequivalent and 
stable product, and adequately blinds the clinical dosage form. However, if comparator 
dosage form must be manipulated (e.g. milled, over-encapsulated, etc.), pre-formulation 
studies may have to be performed, including dissolution rate, moisture, particle size, 
hardness, physical size and weight (for solid dosage forms) and accelerated excipient 
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compatibly studies. Also, formulation studies have to be performed, including short-term 
stability, excipient effects, comparative dissolution for solid dosage forms, and, depending 
on the degree of manipulation, in vivo bioequivalence testing [157].  
 
 
 
3.2.	  Packaging	  
 
The submission of an investigational new drug must include detailed information 
concerning the packaging component [173].  
IMPs are normally packed in an individual way for each subject included in the clinical 
trial. The number of units to be packed should be specified prior to the start of the 
packaging operations, including units necessary for carrying out quality control and any 
retention samples to be kept [11].  
During packaging of IMP, it may be necessary to handle different products on the same 
packaging line at the same time, so the risk of product mix must be minimized by using 
appropriate procedures, specialised equipment as appropriate and relevant staff training 
[11].   
The selected packaging must be appropriate to enhance stability and compliance. The 
selection of a container depends not only on the physicochemical properties of the drug and 
the intended use of the dosage form, but also the environmental conditions to which the 
product will be exposed and the characteristics of the formulation [14, 174]. Packaging 
materials should not interact physically or chemically with the preparation [39, 173, 174], 
and container selection should take into account characteristics such as visibility, strength, 
rigidity, moisture protection, ease of reclosure, and economy of packaging [174]. 
Waterman et al, also considers that package selection can be based on other considerations, 
such as cost [175].  
Several types of packaging will be employed: the primary packaging (direct contact with 
the product) and the secondary packaging (such as carton). The majority of packaging 
materials are in some degree permeable to moisture and the type of closure employed, such 
as plastic and screw fittings, may also permit the ingress of moisture. Thus, specialized 
packs, using low permeability materials, may be required [14]. Temperature fluctuations 
can lead to condensation of moisture on the product, and with liquids, this can lead to 
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microbiological contamination. But light, oxygen and mechanical damage is also a 
challenge in packaging [14, 39, 173, 176].  
Also, the type of study, and the frequency and duration of the dosing regimen will 
influence the package selection. For example, for a small preliminary study it might be 
preferable to simply manually package into bottles of unit dose systems [173]. But, in 
general, the package should be inert to the product within, be adapted to the study, allow 
for the easiest and most accurate accumulation of clinical data, and offer the greatest 
assurance of patient and site compliance [14, 173].  
In accordance with the methods of use and administration of medicinal products, 
packaging materials, closures and containers can vary with a wide variety of different 
requirements. To ensure the efficacy of a product during its total shelf-life, pharmaceuticals 
must be regarded as a combination of the medicinal product itself and the packaging. 
Only the most commonly used packaging materials and containers are described in table 
11. 
 
Table 11. Packaging Materials and Containers. Adapted from WHO Annex 9 (2002) [176] 
Packaging Materials and 
Closures 
Advantages Examples 
Glass 
First choice; 
Glass can be tested for light 
transmission and hydrolytic 
resistance. 
Bottles for tablets, injection 
syringes for unit- or multi- 
dose administration 
 
Plastic 
Unbreakable; 
Collapsible. 
Bags for parenteral solutions. 
 
Metal (aluminium and stain- 
less steel are the metals of 
choice for both primary and 
secondary packaging for 
medicinal products) 
Provide excellent tamper-
evident containers; 
Strong; 
Impermeable to gases and 
shatterproof; 
The ideal packaging material 
for pressurized containers. 
Tubes, packs made from foil or 
blisters. 
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The quickest route to a package product is to use bottles, but in the case of complicated 
dosing regimens, compliance may be compromised [173]. On the other hand, blister cards 
allow that correct dosage is taken at the proper time, which directions indicate for used 
printed on the card. Of course, this assumes that the patient remembers to take the 
medication [173, 177].  
According to Pilchik [177], in addition to help patients following drug regimens, blister 
packs can also protect drugs over a long shelf-life, and are portable. Advocates of blister 
packaging cite some advantages of blister packaging:  
• Product integrity; 
• Product protection; 
• Tamper evidence; 
• Reduced possibility of accidental misuse;  
• Patient compliance. 
 
Aluminum foil is the usual choice of backing for the blister unit [173]. To ensure 
functional properties of blister packages, the quality of starting materials, as well as the 
sealing process validity in the packaging process are most important. In particular, cold 
form blisters have to meet high standards, as they are commonly used to protect moisture 
sensitive products. The investigations of Muhlfeld et al, using different grammages of heat 
seal lacquer, showed that the influence of heat seal lacquer grammage on the quality of 
blister packages seems commonly overestimated [178]. 
Regarding to closures, they are used for the purpose of covering drug containers after the 
filling process, and should be as inert as possible. They should not give rise to undesired 
interactions between the contents and the outside environment, and should provide a 
complete seal. Besides their protective function, closures must also allow the easy and safe 
administration of the drug [176]. 
Depending on the type of container, closures may have different shapes and sizes, such as 
stoppers for infusion or injection bottles or plungers for prefilled syringes. A special design 
of stopper may also be required for some pharmaceutical production processes such as 
lyophilization [176]. 
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3.2.1.	  Stability	  Testing	  in	  Clinical	  Packaging	  	  
 
In the selection of a package suitable for a clinical trial falls into the product evaluation on 
the following characteristics [173]: 
• Sensitive to moisture (solid dosage forms); 
• Light sensitive (solid and liquid dosage forms).  
 
It is the research pharmacist’s duty to stress-test the drugs in storage using factorial 
combinations of [39]:  
• Low and high temperatures; 
• Low and high moisture; 
• Exceeding the labelled drug shelf-life; 
• Exposure to bright and subdued light (in some case clear and amber glass bottles). 
 
The needs of the product must be defined, and the packaging must reflect the needs. It 
should avoid the mistake of package first and discover later that the package failed to 
protect the product. Component selection should be based on data, not on expediency 
[173]. Table 12 describes some of the products needs of sensitive products and the 
solutions for packaging them.  
 
 
Table 12. Solutions for Packaging Sensitive Products  
Product is very sensitive to moisture 
Desiccants may have to be added to the 
container or suitable film select that will afford 
moisture protection [154, 173]. 
Product is light sensitive 
Some sort of light protection is required, like 
amber film, opaque blisters, opaque hard gelatin 
capsule shells [154, 173]. 
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3.3.	  Labelling	  
	  
Labelling is an important and integral part of the approval of an IMP in clinical trials 
[173], and it should comply with the requirements of Directive 2003/94/EC [11, 179]. 
The label has to be permanently attached to the container. The challenge is increased in 
multinational trials, in which the necessity arises to give information in several languages 
(multi-lingual trials).  
The compliance with the labelling requirements is important for all clinical trials during 
drug development, since non-compliance may cause problems during the later approval 
process for the marketing authorisation application because this may be regarded as non-
compliance with Good Clinical Practice (GCP) [179]. 
The regulatory affairs manager is responsible for the labelling of a medicinal product, and, 
therefore it should coordinate the decision process for the labelling in clinical trials, also 
because this labelling is part of the basis for the future labeling [179].  
The basic information on the label should provide the patient’s name, study phase, trial 
reference code, batch number, pharmaceutical dosage form, route of administration, 
quantity of dosage units, directions for use, any special warning or storage requirements, 
expiry date and investigator’s name and address, along with an indication that the drug are 
“for clinical trial only use” and should “keep out of reach of children” [11, 14, 179, 180]. 
Furthermore, the sponsoring company’s name and address should also appear [14].  
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CHAPTER	  4	  
Handling	  Clinical	  Trial	  Supplies	  
	  
The clinical trial supply chain is an enormously complex process. Ensuring that supplies 
arrive at the trial sites on time and in good condition is a challenge that clinical trial supply 
chain managers face in global distribution. Effective distribution requires a knowledge of 
regulations in trial countries, qualified suppliers and storage infrastructure, and control of 
supply temperature and conditions for the duration of delivery [181]. 
The clinical trial material supply chain comprises the planning and scheduling of all 
transactions, operations and organizations during a trial, beginning with API 
manufacturing, followed by drug manufacturing and distribution to the clinical sites, and 
ending with dispensing the drugs to patients at each clinical sites [182, 183]. Figure 12 
represents schematically the typical clinical trial supply chain.    
 
	  
	  
Figure 12. The Traditional Clinical Trial Supply Chain Model. Adapted from Klim (2009) [184] 
	  
Traditionally, the pharmaceutical industry uses batch processes in the manufacture of 
pharmaceutical products. Since these batch facilities are usually shared across various 
products, especially for the quantities needed for clinical trial, it is necessary to decide on 
the order and timing of the products to be produced. These decisions can have a large 
economic impact on the company at the clinical trials stage, because missing the delivery 
of trial dosage to patients can significantly delay completion of the trial, and consequently, 
delay the time to market, which in turn can mean increased costs [182, 183].  
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The key technical challenge in managing a clinical trial materials supply chain are to meet 
the needs from clinical sites, minimizing delays but also oversupply, and to ensure that 
unused materials are not re-routed to others clinical sites [182, 183].  
The distribution of clinical trial supplies presents several challenges that can be differently 
identified by the involved staff: 
• Supply-chain managers point several problems in clinical operations [185]:  
o Failure by clinical operations to provide accurate patient-enrollment forecasts;  
o Lack of resources and capacity in clinical operations and distribution;  
o Lack of processes and distribution lanes for new country distribution; 
o Poor clinical visibility and interactive-voice-response-system (IVRS) 
performance.  
• Clinical operations personnel point weaknesses in supply-chain [185]: 
o Increased globalization of clinical trials and the resulting problems in rest-of-
world distribution management that cause delays in receiving clinical trial 
material (CTM) on time. These problems involve delays in the customs-
clearance processes, a lack of distribution capacity, and poorly established 
distribution lanes.  
 
Other concerns in the supply-chain include poor planning processes in clinical contract 
manufacturing that can cause delays, as well as long lead times for comparator sourcing. 
Another cause for delay in CTM supply relates to securing internal approvals for sourcing 
and contract-manufacturing arrangements. “A lack of a framework and direction on 
approval rules and policies can cause undue delays,” says Handfield and McCormack 
[186]. Defining more clearly and streamlining the approval process through improved 
documentation, the use of contract-manufacturing and sourcing approval coordinators, and 
automation of the approval process, are some actions to address these problems. 
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4.1.	  Product	  Handling	  Parties	  in	  the	  Clinical	  Trial	  
	  
The clinical trial system requires cooperation of diverse groups, including personnel from 
the pharmaceutical company’s medical department, biostatisticians, investigators, trial 
subjects, representatives of national and international regulatory organizations, 
manufacturing personnel, packaging personnel, and sometimes representatives from 
contract research organizations (CROs) and other third-party vendors [187].  
All personnel involved in distribution activities should be trained and qualified, based on 
written standard operating procedures (SOPs). Personnel should receive initial and 
continous training relevant to their tasks, in order to ensure quality of the product [188].  
 
 
4.1.1.	  Sponsor	  
	  
The sponsor is generally a company, institution or organization which takes responsibility 
for the initiation, management and financing of the clinical trial [11].  
 
	  
4.1.2.	  Investigator	  
	  
Clinical investigators are composed by physicians who provide the drug to the patient, and 
they are sometimes also responsible for reordering new drug supplies [187]. They are 
responsible for the conduct of the clinical trial at a trial site, and the responsible leader of a 
team of individuals involved in the conduct of trial [11]. However, they may have 
difficulty keeping track of various SPOs, storage conditions, minimum inventories, and 
other rules related to a range of studies and products, and, therefore, pharmacists and study 
coordinators plays also an important task in help handling the IMP. Investigator 
responsibilities include: 
• Subject recruitment; 
• Medical care of subjects; 
• Collection of subjects’ informed consent forms; 
• Communication with Institutional Review Board (IRB) and Independent Ethics 
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Committee (IEC); 
• Protocol compliance; 
• Investigational medicinal products; 
• Randomization and blinding procedures; 
• Data reporting; 
• Safety reporting. 
	  
	  
4.1.3.	  Pharmacists	  
	  
Investigational sites have, usually, one or two dedicated clinical trial pharmacist, despite of 
the current constraints in health service funding. The pharmacy team should often meet 
with the investigator team during the study [189].  
The pharmacist should be responsible of store the IMP, separately from normal pharmacy 
stock, in an area with restricted access. IMPs that are returned by patients or have expired 
must be stored separately from unused IMPs. Also, the pharmacy staff must undertake 
regular temperature monitoring of IMPs storage facilities, and these records archived 
[190]. A complete summary of drug dispensing, as well as records of procedures and 
responsibilities should be safe with the pharmacist [191]. 
In summary, the tasks of the pharmacist during a clinical trial are [190, 192, 193]: 
• Receipt and recording of the safe delivery of IMPs; 
• Safe handling and storage of IMPs; 
• Preparation and dispensing of IMPs in accordance with professional standards 
(including dispensing against an appropriate prescription, maintaining drug 
accountability records and ensuring that all IMPs are labelled with the appropriate 
pharmacy label); 
• Return of unused IMPs; 
• Reconciliation of IMPs; 
• Maintaining a pharmacy study file; 
• Training of clinical trial pharmacy staff. 
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4.1.4.	  Study	  Coordinator	  	  
	  
The Clinical Research Coordinator (CRC) is a specialized research professional working 
with and under the direction of the clinical principal investigator.  While the principal 
investigator is primarily responsible for the overall design, conduct, and management of 
the clinical trial, the CRC supports, facilitates and coordinates the daily clinical trial 
activities and plays a critical role in the conduct of the study.  By performing these duties, 
the CRC works with the investigator and sponsor to support and provide guidance on the 
administration of the compliance, financial, personnel and other related aspects of the 
clinical study [194]. 
The study coordinator responsibilities include [192]: 
• Patient recruitment activities, supporting the investigator; 
• Completing case report form; 
• Transmitting study data; 
• Scheduling patient visits; 
• Meeting with principal investigator; 
• Meeting with study monitors; 
• Shipping samples to laboratories; 
• Maintaining inventory and accountability of the investigational product; 
• Closing out the study;  
• Participating in ongoing training.  
 
It is important to highlight that the CRC, and also the principal investigator, works with 
various sponsors or CROs at the same time. These different sponsors or CROs 
communicate at different level of expectations regarding source documentation. If the site 
is not experienced enough, and those professionals do not have a standard procedure to 
follow, they may get confused with variations in guidance they receive. This may 
negatively impact the quality of data [195]. 
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4.1.5.	  Study	  Monitor	  
	  
Accurate drug accountability should be ensured by study monitor, during routine visits 
with the aim to assess the site's drug preparation and dispensing procedures, as well as 
subject compliance, and proper drug storage [196]. 
Monitors should confirm that all supplies are accounted for and returned or destroyed, and 
any discrepancies should be investigated and resolved before site closure. Monitors can 
identify inappropriate practices by reviewing drug accountability documentation, and 
retrain site staff as needed. Proper review of drug records can find poor subject compliance 
with drug administration, incorrect supplies at the site, incorrect drug preparation and 
randomization, and potential unblinding of subjects. Upon noting problems, monitors 
should immediately implement corrective action plans to prevent future occurrences, since 
problems detected early are more easily resolved [197]. 
Drug accountability documentation (that are part of regulatory documents) should be 
simple and useful, and it allows [196]: 
• Document the handling of the study drug from receipt to dispensing and return; 
• Display inventory, lot numbers, dose sizes, stock quantities, and expiration dates; 
• Include shipping invoices, confirmation of receipt, condition upon receipt, and the 
information of when drug was received, dispensed, and returned to the sponsor; 
• Help verify patient clinical records and detect possible lot variations; 
• Help verify patient case report form and detect any incompliance; 
• Help identify patients who may have received the drug, as well as the quantities 
that they may still have in their possession; 
• Support the validity of study data and conclusions drawn from those data. 
 
 
 
4.1.6.	  Patients	  
	  
Trial subjects are responsible for taking the IMP, and they present multiple challenges to 
the packaging group and clinical supply group. For example, subjects might misplace their 
drug supplies or not take the product as labelled [187]. 
	  	  
	   Handling	  Clinical	  Trial	  Supplies	   	  	   	  
87	  Preparation	  and	  Handling	  of	  Investigational	  Medicinal	  Products	  
When supplies are dispensed to subjects for self-administration (ambulatory), compliance 
should be ensured, using, for example, diary cards. Furthermore, in order to assess 
compliance, investigator should ask unused supplies and empty containers. 
In fact, all data obtained from the patient are relevant for the assessment of clinical trial 
results, and patients should be instructed to meet all the criteria for data registration.  
Also, all patients who participated in clinical trials should be followed until the end of it. 
Loss to follow up can change the results and compromising the study. 
	  
	  
	  
4.1.7.	  Contract	  Research	  Organizations	  	  
	  
CRO’s are organizations contracted by the pharmaceutical company to support 
pharmaceutical development, preclinical research, clinical research, clinical trials 
management (manufacturing, packaging, labelling, and distribution clinical materials), as 
well as pharmacovigilance activities [180, 187].   
 
 
4.2.	  Distribution	  of	  Investigational	  Medicinal	  Product	  
	  
Figure 13 shows an example of supply chain. First, the API and drug product are 
manufactured in a silo type organization with departments that have a science focus on the 
development of API and drug product. Manufacturing process is obviously a key 
deliverable from those departments. Comparator drug manufacturing can be defined as a 
normal drug product manufacturer, but dynamics are different, typically sourced via 
intermediate entities and it drives the study supply costs significantly. The packaging unit 
for IMP is linked with blinding aspects of the trial [198]. Second, figure 13 also shows that 
IMP is transferred to a distribution network, establishing a proper supply chain for each 
study. The distribution ends at the patient visit in clinical sites, potentially managed with 
interactive response technology from CROs or specific interactive responsive technology 
service providers [198].	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Figure 13. The R&D Supply Chain. Adapted from Bielmeier & Crauwels (2012) [198] 
 
 
Regardless if the activity is internally executed or outsourced, sponsors and contractors 
need to overcome many operational challenges, such as forecasting, planning, 
manufacturing, warehousing and distributing drug product [198]. 
 
	  
	  
4.2.1.	  Warehouses/Depots	  
 
For large global studies, depots are often an integral part of delivering supplies in a timely, 
cost-effective manner. 
Depots should have drug storage facilities compliant with GMP, with controlled room 
temperature and cold-chain storage. Often depots are established in areas where there are 
lengthy customs clearance and import license application processes, complex import 
requirements, and long shipment times due to distance [181]. 
In countries such as Canada and Australia, the deposit delivery is unnecessary, since the 
customs procedures are simplified. But in other countries, such as Argentina, Russia, China 
and India, a deposit is required because of sheer distance, and are countries that require 
considerable time to clean materials [181]. 
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Depots are also advantageous when clinical centers require clinical supplies within a short 
time, and when there are large numbers of patients and sites in one area, reducing the risk 
and cost of cold storage shipments [181]. 
Another important factor in the use a depot is cost, considering that it is far less costly to 
deliver one or two bulk shipments to a depot, than repeated shipments directly to sites, 
which mean also an increase risk. But, it is also important, find out if depot has the 
capability to recover unused supply from the site and ship it back [181].  
The requests for serialized kits3, such as depicted in figure 14, needs to be a highly 
automated process between depot warehouse and order management, in order to ensure 
compliance, avoid errors, and control the costs [198]. Once clinical trial material (CTM) is 
prepared into patient kits, shipment to clinical sites can be dictated by patient enrollment. 
For multicenter studies, initial supplies can be used to open a clinical site where resupply 
frequency is dependent on actual patient enrollment at any given site. During shipment, 
IMPs should be protected against exposure to undesirable environmental conditions, 
maintaining, for example, freezing or refrigerated conditions to ensure product integrity, 
especially in cases of biological products shipment [180].  
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure 14. Content of Patient Kit. Adapted from Bernstein (2002) [154, 180] 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  Assembly	  of	  clinical	  trial	  material	  into	  patient	  kits	  is	  known	  as	  secondary	  packaging,	  since	  the	  actual	  drug	  
product	  is	  not	  exposed	  to	  environmental	  conditions	  during	  this	  operation.	  The	  use	  of	  patient	  kits	  facilitates	  
dispensing	  by	  the	  clinical	  site,	  usage	  by	  the	  patient	  and	  returns	  goods	  accountability	  by	  the	  clinical	  monitor.	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Sponsor pipeline products are becoming increasingly cold chain with the influx of 
biomolecules that needs a strict temperature measurement method. But such methods are 
becoming increasingly costly, often representing a burden for the launch of biomolecules 
[198].  
 
 
 
4.2.2.	  Intermediate	  Storage	  	  
 
Regarding to intermediate storage, a more common approach has been defended in last few 
years, in order to eliminate the intermediate storage lead time at local or country specific 
depots: direct to site shipment from regional hubs [198]. In reality, this is one of the most 
commonly employed strategies. Clinical supplies are stored within a central depot and are 
exported to investigator sites in various countries as required [199].  
But, many companies successfully use a local distribution depot within required countries. 
However, this concept requires application of multiple import licenses, and allows the 
depot to act as a repository for clinical trial supplies [199].  
The next table shows the advantages and disadvantages of direct to site distribution, and 
distribution to local depots.  
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Table 13. Advantages and Disadvantages of Direct to Site Distribution and Local Depots 
Distribution. Based on Shannon (1999) [199]	  
Direct to site distribution Distribution to local depots 
Pros Cons Pros Cons 
Material may be 
labeled with multiple 
languages 
Direct to site shipment 
is not possible for 
some countries 
Reduced transit times 
to investigator sites 
Management of 
multiple local depots 
No pre-allocation of 
supplies to specific 
countries, allowing 
maximum flexibility 
Frequent, low volume 
international shipment 
Single customs 
clearance per depot 
Wastage of supplies 
through initial 
overstocking of depots 
Reduced 
manufacturing 
overages required, 
leading to reduced 
costs 
Depending on the 
countries selected, 
multiple import 
license applications 
may be required 
Reduced shipping 
costs – one large 
international shipment 
to a depot, followed 
by multiple domestic 
shipments will be less 
expensive that 
multiple international 
shipments 
Reduced visibility of 
supplies at depots – 
inventory reports may 
not be as readily 
available 
Greater control of 
supplies reducing the 
amount of unused 
medication 
 Readily available local 
knowledge and 
expertise 
Medication must be 
pre-allocated to 
countries 
   Greater risk of loss 
should there be any 
deviations associated 
with the initial depot 
shipment 
	  
	  
	  
4.2.3.	  Import	  Licenses	  
	  
Emerging markets, such as Asia, Central and Eastern Europe, and Central and Latin 
America, offer an opportunity to reduce R&D time and costs if managed appropriately. To 
conduct these trials successfully it is critical to appreciate the complexities of shipping to 
emerging countries and ensure that any potential benefits are not lost through a lack of 
understanding or poor planning [199, 200]. 
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One of the largest hurdles to pharmaceutical companies conducting trials in emerging 
countries is the import requirements [201]. 
Clinical trial supplies should be available at clinical sites when are required, to ensure the 
success of any study. The import of clinical supply materials is highly regulated and needs 
to comply with country specific regulations. Failure to comply with import regulations 
could mean the end of a study, due to, for example, the refusal of a carrier for transporting 
supplies. Trials occurring in emerging markets present some additional challenges, such as 
[199]: 
• Political instability; 
• Poor transport infrastructure; 
• Poor training of staff; 
• Time required to obtain appropriate import licenses.  
 
Obtaining an import license for shipment can be a time consuming process, where is 
necessary an accurate completion of documentation. Often inexperience in import license 
application or lack of information during preparation of the data to be submitted, leads to 
delays in the initial application, as well as customs delays, because of the use of incorrect 
information. In most cases an entirely new import license application may be required. 
Country specific regulations should be fully understood and complied to maintain a fluid 
supply chain. In addition, it is important to have knowledge of public holidays and 
regulatory agency “shut downs”, because the lack of this information could also face 
considerable delays in an import license application, being not processed promptly [199]. 
Generally the CRO will arrange the import licenses and permits for the clinical trial, and 
the supplies company will produce the customs invoices [201].   
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4.2.4.	  Control	  of	  Transport	  Conditions	  
	  
4.2.4.1.	  Shipment	  Logistics	  	  
	  
Shipping volumes of pharmaceutical drugs need logistics specialists, the national or 
international transport carriers, freight forwarders, and brokers that make it all happen. 
Depending upon how the product is classified, in terms of International Air Transport 
Association regulations, different requirements would apply. Additionally, the importing 
country may also impose their requirements. It makes sense to choose a customs broker 
with offices located in the country closest to the shipping source or distribution point, with 
expertise in the regulations of that country. Depending upon the size of the shipment, the 
clinical supplies unit may need to contract a courier to transport the CTMs from the 
company to the investigator or depot distribution site. The advantage is that the properly 
qualified courier company will know all of the key requirements of importation and 
exportation to assure delivery at the clinical site [202]. 
Although it is important to produce quality CTM, it is also important to provide CTM 
worldwide, safely and in a timely manner. Use of various services like an express mail 
courier (i.e., DHL and FedEx), freight forwarders, shipping agents, and truly specialized 
couriers (i.e., World Courier) should be chosen based upon the product that needs to be 
shipped, its size and weight of the shipment [203]. Their ability to know and satisfy the 
requirements in the receiving country (import and export requirements) is essential. This 
should include, but not be limited, to the following services [202]: 
• Refreshing cold packs or dry ice; 
• Expedited delivery of the product;  
• Ability to transport large quantities;  
• Ability to transport hazardous or flammable products; 
• Knowing the requirements in both the importing and exporting countries;  
• Ability for rapid customs clearance; 
• Obtaining required documentation;  
• Paying duties or customs charges; 
• Having a general knowledge of the infrastructure within the importing country. 
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The vehicles and equipment used to distribute clinical supplies should prevent exposure to 
conditions that could affect their stability and packaging integrity, as well as any kind of 
contamination. So, the vehicles, containers and equipment should be kept clean and dry, 
and free from accumulated waste [188]. Written procedures and records for cleaning 
should be in place to ensure the quality of the IMP, but also management should approve 
the agents used for the cleaning [188].  
One of the trends happening in the industry is that the traditionally regional transport 
companies are building more extensive networks in order to maximize their business. 
Another recent trend among logistics specialists has been a shying away from airfreight 
[203].  
	  
	  
	  
4.2.4.2.	  Temperature	  Control	  During	  Transport	  –	  Good	  Cold	  Chain	  Management	  
Practice	  
	  
The distribution of temperature-sensitive drugs represents an increasingly important 
process of the global pharmaceutical supply chain.  
Of the 427 billion € of pharmaceutical product sold world wide in 2005, more than 10% 
were biopharmaceuticals, which grew faster than the traditional pharmaceutical market 
[204].  
Clinical trials run on a global scale and in some cases in markets with less than ideal 
logistics infrastructures, creating a challenging distribution environment because of 
shipping large volumes of refrigerated patient kits worldwide, while maintaining and 
documenting appropriate environmental conditions. Moreover, the globalization of clinical 
trials needs specialty couriers and contracted depots to improve the performance of the 
supply chain and build a more robust clinical trial distribution process [204].  
The impact of cold chain failure on clinical trial material may lead to the following risks 
[205]: 
• The patient could be administered an unsafe product; 
• Lack of compliance with global regulatory and standards-based requirements can 
increase liability; 
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• Thermal variability can lead to inconsistency of results between and within batches; 
• The shipment can be rejected by the Quality Department therefore leading to costly 
delays.  
 
The debate between appropriate shipping and storage temperatures requires supporting 
data and a transportation control strategy [206]. John Taylor and Ian Holloway, from the 
Medicines and Healthcare Products Regulatory Agency in United Kingdom, state in an 
article: “the need for control is even greater for clinical trial materials because, in early 
phase studies, the stability of the material may not have been fully established. The 
redeployment of CTM to different trial sites can present additional risks to these materials” 
[207]. 
Four primary regulatory trend have been identified [204]:  
• Accountability for the cold chain should be shared across all supply chain partners; 
• Increased oversight, management, and control of environment conditions across the 
entire supply chain; 
• Increased importance of the temperature control and monitoring; 
• Heightened priority of patient safety – with focus on product quality.   
 
The common goal of all partners should be common: ensuring that each patient and site is 
supplied with the correct medication, at the right time, and in the right condition.  
	  
	  
	  
4.3.	  Stock	  Management	  
	  
4.3.1.	  Site	  Activities	  	  
	  
IMP accountability is the process for accounting and documenting the use of the IMP, 
keeping in mind compliance and potential loss of the medication [195, 208]. It includes:  
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• Receipt and inventory of investigational drugs;  
• Storage of IMPs, including a limited-access area and proper temperature 
conditions;  
• Dispensing of IMP;  
• Return of IMP; 
• Maintain accurate and complete drug inventory records, including the recording of 
dates, lot numbers, date the drug is received, and date dispensed to a subject or 
returned to the sponsor.   
The research pharmacist must properly store and dispense all IMPs and maintain accurate 
dispensing and inventory records. 
	  
	  
4.3.1.1.	  Receipt	  
	  
The receipt of each shipment of study medication or device should be confirmed in writing 
by the investigator or pharmacist (or other authorized personnel), who will be instructed to 
return a completed “acknowledgement of receipt form” immediately [209]. After receipt, 
supplies must be checked against any shipment form to ensure that IMPs received 
corresponds with what was requested. The following checks should be made [208]: 
• Ensure supplies are correctly addressed; 
• Ensure all packaging intact; 
• Ensure that the quantity, batch numbers, name of manufacturer, correspond with 
shipment form. 
 
If any problems are detected, such as missing or broken items, defects in labelling, or 
inappropriate temperature control, sponsor or CRO should be immediately informed. 
[209]. Any discrepancy is a big problem, not only because of the regulatory violation, but 
because it potentially endangers the integrity of the study [208].	  	  
Once received the investigational products from sponsor, the pharmacist or principal 
investigator must send to the sponsor a filled clinical supplies acknowledgement form 
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(table 14) through mail or courier systems [208]. 
 
Table 14. Clinical Supplies Acknowledgement Form. Adapted from Krishna et al (2012) [208] 
Clinical Supplies Acknowledgement Form  
Study No: Received by: 
Received date/Time: Received through (by Courier/by Post): 
Storage Condition: Packaging condition: 
Any special condition: Number of container received: 
Total quantity in test container: Total quantity in reference container: 
Any discrepancy:  
 
The exact date of receipt of the clinical supplies should be promptly recorded, so that the 
monitor can determine that the supplies were secure and correctly stored during the entire 
period of shipment [209].  
After the clinical study supplies have been sent to the study site, the monitor must verify, 
as soon as possible, that the supplies have arrived satisfactorily. Monitor should check the 
condition of the supplies before subjects receive medication. The study monitor will verify 
that the amount shipped matches the amount acknowledge as received, and, if there is a 
lack of reconciliation, recruitment may be delayed until the situation is resolved [209]. 
Failure to check the receipt of IMP into pharmacy stores may result in an incorrect audit 
trial of drugs received, incorrect drug accountability or the drugs received being stored in 
incorrect temperature conditions. This could result in IMP being wasted and cancellation 
of patient recruitment.  
	  
	  
4.3.1.2.	  Storage	  
	  
Evidence of careful control at the study site is imperative, but is difficult to standardize the 
situation across many study sites and many countries [209].  
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According to the ICH Guideline for GCP, after checking the supplies received at site, they 
should be stored in appropriate conditions, as specified by the sponsor [210]. The drug 
storage area should be secure. It should be locked where appropriate and access to the 
supplies limited where possible to investigators and research nurse. 
The study monitor must be trained to check correct storage and documentation, and ensure 
that all site personnel are fully trained and informed [209].   
During the process of pharmacy, the required storage conditions for the IMP should be 
ascertained by reference to [211]:  
• The Investigator’s Brochure or Summary of Product Characteristics;  
• The Protocol.  
 
The main concern for appropriate environmental conditions is usually temperature 
requirements, especially with biologic supplies that are usually to be kept refrigerated 
between 4-8ºC. But light, humidity and room temperature are also important, because such 
terms could have different meanings in different counties [209].  
There are also two quarantine storage areas for IMP, one for refrigerated IMP (2ºC to 8ºC) 
and another at room temperature (15ºC to 25ºC), which should be used to store IMP if the 
product has expired, or is awaiting certificate of release, or has been subject to a 
temperature excursion. Ambient and refrigerated supplies returned by the patient must be 
stored in a box labeled “Clinical Trials Returns”. Once they have been reconciled and 
logged in the relevant pharmacy clinical trial file, they will be stored in the clinical trials 
office, in a locked cupboard separated from normal hospital stock [211]. A record of 
storage temperature conditions should be maintained for each location where current 
supplies of IMP are stored [211]. At each monitoring visit, the monitor will ensure that the 
correct procedures are being followed [209]. 
 
 
4.3.1.3.	  Dispensing	  
	  
All investigational drugs should be signed out on Investigational Drug Accountability 
Form by the pharmacist who dispensing the drug (table 15). Each separate drug dispensing 
form should be used for each protocol [208]. 
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An investigational or study drug may be dispensed only upon receipt of a written order by 
the principal investigator [212]. However, there are additional requirements for dispensing 
investigational drugs, which include: verification of protocol approval and informed 
consent, record-keeping, preparation or packaging of final product, labeling of dispensed 
product, and disposal of unused or partially used medications [213]. 
All relevant information and documents for proper and safe drug dispensing must be 
widely available. The pharmacy staff needs to know not only how to prepare and dispense 
the drug but also how to complete dispensing records and maintain inventory, in order to 
successfully adhere to the clinical drug protocol. Pharmacists who dispense IMPs must be 
familiar with the drug information and study design, in order to assist the clinical staff with 
management patient [212].   
	  
Table 15. Drug Dispensing Form. Adapted from Krishna et al (2012) [208] 
Name of the Investigational Product (Test/Reference): 
 
Batch Number: 
 
Expiry Date: 
 
Period Date Line 
clearance 
Yes/No 
Initial 
balance of 
drugs 
No. of 
units 
dispensed  
No. of 
units 
dosed 
Remaining 
Units 
Allotment of 
subjects as  
Per Randomization 
Schedule 
        
        
        
 
Dispensed by: 
 
 
Checked by: 
	  
There are situations relatively uncommon, in which the investigator carries out the storage 
and dispensing of the IMP, such as when the immediate administration of or facile 
accessibility to the IMP is necessary to ensure adherence to trial methodology [213]. This 
situation requires policies and procedures successfully implemented to ensure that the 
pharmacy maintains some oversight of investigational drugs [213].  
Since the use of drug in clinical trials within the institutional setting must be done in 
accordance with a number of regulations, guidance, and standards, including GCP 
guidelines, local institutions policies and procedures, and the study protocol itself, in a 
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recent article, Siden et al [212] describes a tool that can be implemented by pharmacists to 
prepare instructions for dispensing, inventory management, and accountability of IMPs in 
a consistent, concise, and organized manner. The template is divided into three major 
sections [212]: 
• Dispensing instructions (includes aspects related to the correct distribution of the 
drug, including dose calculation, calculation worksheets, drug preparation and 
dispensing procedure, and documentation of drug dispensing); 
• Study design and drug information (provides background information described in 
the protocol and the investigator’s brochure, including pharmacokinetics, adverse 
effects, and concomitant drug restrictions of the investigational drug); 
• Study maintenance information (included instructions on drug ordering and 
disposition and information on the sponsor as it relates to sponsor visits and audits). 
  
During an audit, a random sample of dispensing records and inventory log forms are 
inspected [213]. Dispensing by the pharmacist is a crucial step in the handling of the 
investigational drug, since the most common pitfalls identified during sponsor audits are 
[195]:  
• No documentation that oral drug was provided to subject and/or returned by subject 
with pill count; 
• Poor documentation regarding drug diaries; 
•  Poor prescription practices.  
 
Since source documentation related findings are the most commonly cited during 
inspections and audits [214], the clinical site should develop SOPs for good documentation 
[215]. The SOP should be shared with the sponsor/CRO and agreed before the start of the 
trial. SOP should also address aspects including consenting process, verifying eligibility, 
use of right tools such as diaries, source document worksheets, copies of prescriptions, etc; 
ways to avoid multiple records, and in case of multiple records, should define the source 
for the study, method of corrections, review of safety labs and other reports. Documented 
procedure at site level should encompass management, maintenance, archival and retrieval 
of source documentation, in order to have measures for continuous improvement and 
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maintaining high-quality data, because is extremely important that sites develop process 
for quality control [195]. 
Since drug accountability records are part of the regulatory documents, they must be 
maintained in close proximity to the area where the study drugs are stored or dispensed, 
available for inspection when the study is monitored or audited [216].   
 
 
 
4.3.1.4.	  Patient	  Instructions	  
	  
The investigator should explain the correct use and storage of IMP to each patient enrolled 
in the study at the start of the trial, and should also check, at appropriate intervals, that each 
patient is following the instructions properly. The patients should also be instructed to 
return all unused supplies, including empty containers at each visit. The supplies should be 
reconciled against the supplies dispensed to the patient and the supplies used by the 
patient, according to the sponsor requirements. The sponsor company should provide a 
drug-dispensing log and the investigator or pharmacist should completed it at each time 
that supplies are dispensed or returned.  
Patients must comply with investigator’s instructions by taking the recommended number 
of doses at the correct times, coming to the clinic as directed, being cooperative and honest 
with the staff who are conducting the study, and adhering to all other aspects of the study, 
such as, for example, avoiding the forbidden concomitant medicines and following the 
recommended diet [217-219]. Table 14 shows some examples of elements for patient 
instructions. 
Especially if supplies are dispensed to subjects for self-administration (ambulatory), 
methods to ensure compliance (e.g., diary cards, instructions on labeling, supervised 
administration) and check compliance (e.g., tablet counts, plasma/urine assays, diary card 
review) must be in place [209, 220]. At each visit, the study subjects should be asked to 
return all unused supplies and empty containers to the investigator, which will be checked 
for compliance assessment. In the monitor’s visit all relevant documents will be reviewed 
(e.g., case report forms (CRF) medication/device inventory, dispensing forms) to ensure 
that the data in the CRFs reflect the subject’s compliance with the study [209].   
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Table 16. Examples of Elements for Patient Instructions 
Patient Instructions 
Name of medication  
Medication dosing and scheduling 
Any special storage instructions for the 
investigational drug  
List of medications that must not be taken 
concurrently  
List of any foods that must not be eaten  
Reminders to return all medication vials or 
blister packs, even if used or empty (for drug 
accountability and compliance assessment) 
Reminders not to share the medication with 
anyone else and to keep the medicine in a secure 
place.  
 
 
 
4.3.1.5.	  Return	  and	  Destruction	  of	  IMP	  
	  
The final step in the drug accountability process is the overall reconciliation of supplies 
and destruction. The reconciliation of initial inventory and the final returns must be 
undertaken, and any discrepancies, and reasons for any non-returns, must be explained and 
reported to the sponsor company [208, 221]. This process requires a lot of attention, as 
well as drug dispensing, since inadequate drug accountability belongs to the list of the 
most common findings observed during recent inspections [222]. All unused and returned 
medications or empty containers, must be stored securely at the study site until retrieved by 
the monitor [209]. In addition, the records should distinguish between unopened (not 
dispensed) and unused (by study subjects) supplies, identify broken or lost supplies, and 
show 95%-100% of supplies are accounted for [208, 216]. The study monitor will check 
the returned supplies and verify that they reconcile with the written specifications [209]. 
Final disposition and destruction must be carefully documented to allow assessment of 
possible detrimental environmental impact [209].  
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Destruction of returned IMP by the sponsor or CRO may not take place until the final 
report has been prepared. Currently, specialists advise that returned medication should be 
destroyed throughout the clinical study duration. The destruction process must be clearly 
documented and details of the method of destruction explained. However, in exceptional 
cases, unused study medications, such as cytotoxic and radio-labeled products, may be 
destroyed at the site, with appropriate documentation [209].     
	  
	  
	  
4.3.2.	  Computerized	  Systems	  in	  Clinical	  Trial	  Supply	  Chain:	  IVRS/IWRS	  
	  
A large proportion of the cost of implementing a clinical trial is attributable to the 
production and management of IMP [223]. As a result, the management and distribution of 
IMP by computerized systems, in association with a telephone (IVRS) or web interface 
(IWRS), has becoming increasingly common [223]. For example, IVRS is a system that 
enables real-time monitoring of inventory in the clinical trial supply chain [183, 224, 225]. 
Such systems have been developed further into interactive web based systems (IWRS) 
utilizing the internet [226]. Both, IVRS and IWRS were developed to facilitate overall 
drug management and expanded to assist with dose titration, unblinding and expiry date 
update [226].  
IVRS use the telephone as a means of inputting data, where pre-recorded prompts, that list 
the various options available or that request responses to particular questions, are played 
for the user. Data are entered and written to the underlying databases by using the 
telephone touch-tone keypad [225]. 
In an IVRS, medication packs are uniquely numbered not by subject number, but by 
medication pack number [225, 226]. Any pack can be assigned to any subject within the 
same treatment group. Rather than containing the entire medication supply for an 
individual subject within a pack, optimal application of this approach involves packing 
medication in sufficient packs to treat a subject for a complete dispensing interval. Because 
complete dispensing units may be allocated to other subjects in the same treatment group, 
using IVRS can reduce wastage of medication that would traditionally occur when a 
subject withdraws from the study [226]. 
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Figure 13 illustrates how an IVRS is used to dispense medication packs to subjects, and 
how to maintain appropriate stock levels at site. 
 
 
	  
Figure 15. Medication Dispensing and Automated Site Inventory Control Using IVRS. Adapted 
from Byrom (2002) [225] 
	  
This figure shows the interaction of three main sites - the IVRS inventory database, the 
drug distribution depot (a pharmaceutical company or an external packing and distribution 
agency), and the study site. When an IMP arrives at a site, the site investigator or 
coordinator makes a call into the IVRS, indicating that want to dispense medication and 
identify the subject that requires medication. The system reports the medication pack 
number that should be dispensed to that subject, with reference to the known site 
inventory. An automated fax or e-mail confirms this information. One of the advantages of 
using a computerized system to control dispensing of IMPs is the ability to maximize the 
use of study supplies by allocating packs in expiry date order [224, 225].  
For example, the IVRS dispenses the current medication pack, identifies that the stock at 
the site for that treatment has fallen to a predefined minimum level (trigger level), and 
sends an electronic request to the drug distribution depot for a consignment of additional 
supplies to be sent to the site. This request lists the number of packs of each treatment that 
should comprise the consignment. Sometimes the IVRS will dictate the pack numbers that 
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should be sent; other times the drug distribution depot will report back electronically which 
pack numbers were issued in the consignment. Then the medication is shipped to the site, 
where the CRC or pharmacist makes another call into the IVRS to register the 
consignment’s arrival. Missing or damaged packs can be identified during this call, 
possibly triggering an additional consignment. Finally, the IVRS database updates the 
study site inventory to include the new packs that are then available for dispensing to 
future clinical trial subjects [225]. 
Interactive voice response systems represent a valuable tool to the clinical study manager, 
not only to perform randomization, emergency code-break, and medication supply 
management, but also to collect subject-recorded data, both during the study and in the 
study pre-qualification activities during the recruitment period [225, 227]. However, for 
studies using a simple design and where the availability or the cost of the drug is not an 
issue, then IVRS would not be appropriate [181, 226]. 
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CHAPTER	  5	  
Concluding	  Remarks	  
 
	  
The preparation of an investigational medicinal product involves a multidisciplinary team 
and all efforts should be made to keep the same goal in mind. In fact, nowadays, 
developing drugs or devices for medical use is an expensive and lengthy business. It may 
cost several billion US dollars, and take more than 12 years to develop one single licensed 
drug, but efforts have been done to reduce development time, mainly through the 
contribution of high-throughput screening strategies, that improve the selection and 
optimization of molecules able to interact with high affinity and selectivity to the 
molecular target. Reduce the costs and time in the drug development is the most important 
challenge that pharmaceutical industry has to deal with. 
During the development of IMP, special attention should be given to the solubility, as well 
as bioavailability assessment and bioequivalence studies, since they are the most 
challenging steps in the early phase of preparation of IMPs. Concerning the IMP 
production, the critical aspects, such as comparators, blinding and package, will determine 
the success of the entire clinical trial. Finally, when the IMP is fully prepared, it enters in 
the different clinical trials phases, with the aim of providing a range of information, such 
as efficacy and safety, which will determine its market introduction, bringing benefit to 
health. This whole process must meet a series of requirements previously established, and 
adequate trained staff, in order to minimize the costs associated with the development of 
the IMP, as well as accelerate its market entry. 
The knowledge and training in the pharmaceutical medicine has been a significant 
contribution to the new era in drug development. Therefore, this work may help new 
students and new professionals, bringing some knowledge about the preparation and 
distribution of the investigational medicinal products.  
However, it is relevant to point out certain limitations. This work addresses two major 
chapters: the preparation of the investigational medicinal products and their handling 
during the trial. Although there is a wide range of information on the preparation of 
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investigational medicinal products (pre-formulation, formulation, packaging, labeling, 
etc.), little information is available on logistics. Actually, there are several guidelines on 
the distribution and good clinical practices, but actual cases that describe the practice of 
procedures are hard to find in the available recourses. It was intended to summarize the 
process of preparation of medicinal products, addressing only the most relevant topics. 
However, in a future work it would be interesting to explore deeper the distribution of 
investigational medicinal products, addressing key findings of audits and find tools and 
procedures to avoid noncompliance. 
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